Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 714
Healthy volunteers: no

Brief summary:
The primary objective of this pragmatic study is to compare the time to first moderate or severe COPD exacerbation in patients, not controlled on their current therapy, randomized to Stiolto Respimat versus triple therapy over 12 months of treatment

The secondary objectives of this study include:

1. To compare the annual rate of moderate or severe COPD exacerbations for patients on Stiolto Respimat with patients on triple therapy.
2. To compare the time to first severe COPD exacerbation in both treatment arms.
3. To compare the annual rate of severe COPD exacerbations in both treatment arms.
4. To compare the proportion of patients with moderate or severe COPD exacerbations in both treatment arms.

Detailed description:

Arms:
arm 1: None arm 2: ICS (Inhaled Corticosteroid) plus LABA (Long-Acting Beta Agonist) plus (Long-Acting Muscarinic Antagonist)

Interventions: intervention 1: Stiolto Respimat intervention 2: ICS (Inhaled Corticosteroid) (Triple therapy) intervention 3: LABA (Long-Acting Beta Agonist) (Triple therapy) intervention 4: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Intervention descriptions: intervention 1: Duration - 12 months intervention 2: Duration - 12 months intervention 3: Duration - 12 months intervention 4: Duration - 12 months

Protocol document:
Prot_000.pdf: 
 
PROTOCOL No: 1237-0064 – Boehringer Ingelheim COPD Study 
 
 
 
 
 
 
 
 
 
 
Randomized Pragmatic Clinical Trial in a Community-Based Setting 
Comparing STIOLTO® RESPIMAT® vs. ICS-LABA plus LAMA in Patients 
with COPD 
The AIRWISE Study: Assessment In a Real World setting of the effect of Inhaled 
Steroid-based triple therapy versus the combination of tiotropium and olodaterol on 
reducing COPD Exacerbations 
 
 
Protocol No.  1237-0064 
 
 
 
 
 
Fax: 
 
 
 
May 9, 2018 
Version 2.0 
 
 
 
 
 
 
This document and its contents are the property of Boehringer Ingelheim 
and are confidential.  Unauthorized copying or use is prohibited. 
Doc. No.: c23740530-01


Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
3 
 
Study Physician Agreement: 
I have read the protocol “Randomized Pragmatic Clinical Trial in a Community-Based Setting 
Comparing STIOLTO® RESPIMAT® vs. ICS-LABA plus LAMA in Patients with COPD” and 
agree to ensure that all staff members involved in the conduct of this study are informed of their 
obligations in meeting the commitments in accordance with it. 
I acknowledge that I am responsible for overall study conduct. I agree to personally conduct or 
supervise the described pragmatic trial. 
 
Signature:    
 
 
 
 
 
 
Date:  
 
 
 
Print Name:   
 
 
 
 
 
 
 
 
 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
4 
 
TABLE OF CONTENTS 
STUDY APPROVALS ......................................................................................................... 2 
STUDY PHYSICIAN AGREEMENT .................................................................................. 3 
TABLE OF CONTENTS ..................................................................................................... 4 
SYNOPSIS ........................................................................................................................... 7 
LIST OF ABBREVIATIONS ............................................................................................. 11 
1 
INTRODUCTION ...................................................................................................... 13 
1.1 
Background and Rationale .................................................................................................................................. 13 
2 
STUDY OBJECTIVES ............................................................................................... 15 
2.1 
Primary Objectives ................................................................................................................................................ 15 
2.1.1 
Primary Objective Definitions .......................................................................................................................................... 15 
2.2 
Secondary Objectives ............................................................................................................................................ 15 
3 
STUDY ENDPOINTS ................................................................................................. 16 
4 
STUDY DESIGN ........................................................................................................ 17 
4.1 
Overview .................................................................................................................................................................... 17 
4.2 
Practice and Participant Selection ................................................................................................................... 17 
4.2.1 
Physician Practice Eligibility ............................................................................................................................................ 17 
4.2.2 
Participant Recruitment and Eligibility ....................................................................................................................... 18 
4.2.3 
Participant Inclusion Criteria ........................................................................................................................................... 18 
4.2.4 
Participant Exclusion Criteria .......................................................................................................................................... 18 
4.2.5 
Participant Enrollment ........................................................................................................................................................ 19 
4.2.6 
Patient Randomization ........................................................................................................................................................ 19 
FIGURE 1: SCHEMATIC OF STUDY DESIGN ............................................................... 20 
5 
STUDY PROCEDURES ............................................................................................. 21 
5.1 
Enrollment Procedures ........................................................................................................................................ 21 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
5 
 
5.2 
Baseline Visit ............................................................................................................................................................ 21 
5.2.1 
Participant Characteristics ................................................................................................................................................ 21 
5.2.2 
Treatments ............................................................................................................................................................................... 21 
5.3 
PROs............................................................................................................................................................................. 21 
5.3.1 
COPD Assessment Test TM (CAT) ..................................................................................................................................... 22 
5.4 
Study Period ............................................................................................................................................................. 22 
5.5 
Final Visit/EOS ......................................................................................................................................................... 22 
 
 
5.7 
Withdrawals ............................................................................................................................................................. 23 
5.7.1 
Physician Practices ............................................................................................................................................................... 23 
5.7.2 
Participants .............................................................................................................................................................................. 23 
6 
STATISTICAL METHODS ....................................................................................... 23 
6.1 
Analysis Overview .................................................................................................................................................. 23 
6.2 
Study Populations................................................................................................................................................... 24 
6.2.1 
Analysis Populations ............................................................................................................................................................ 24 
6.2.2 
Safety Population ................................................................................................................................................................... 24 
6.3 
Sample Size Determination ................................................................................................................................. 25 
6.3.1 
Power and Sample Size for Primary Objective ......................................................................................................... 25 
6.3.2 
Randomization and Blinding ............................................................................................................................................ 25 
6.3.3 
Interim Analysis ..................................................................................................................................................................... 25 
6.4 
Effectiveness Analysis ........................................................................................................................................... 25 
6.5 
Patient Reported Outcome (PRO) Analysis................................................................................................... 26 
6.6 
Safety Analysis ......................................................................................................................................................... 26 
 
 
 
 
 
 
 
6.8 
Missing Data ............................................................................................................................................................. 29 
7 
AE REPORTING ....................................................................................................... 29 
7.1 
AEs ................................................................................................................................................................................ 30 
7.2 
SAEs.............................................................................................................................................................................. 31 
7.2.1 
Reporting Period of SAEs ................................................................................................................................................... 31 
7.3 
Pregnancy .................................................................................................................................................................. 32 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
6 
 
8 
DATA COLLECTION ............................................................................................... 32 
8.1 
Data Sources ............................................................................................................................................................. 32 
8.2 
eCRFs/EDC ................................................................................................................................................................. 33 
8.3 
Database Development ........................................................................................................................................ 33 
8.4 
Data Quality Assurance ........................................................................................................................................ 33 
9 
STUDY MANAGEMENT .......................................................................................... 34 
9.1 
Regulatory and Ethical Consideration ............................................................................................................ 34 
9.1.1 
IRB/Independent Ethics Committee (IEC) ................................................................................................................. 34 
9.1.2 
Informed Consent .................................................................................................................................................................. 34 
9.2 
Dropouts .................................................................................................................................................................... 35 
9.3 
Record Retention and Access ............................................................................................................................. 35 
10 PUBLICATION OF STUDY RESULTS .................................................................... 35 
TABLE 1: TIME AND EVENTS SCHEDULE .................................................................. 36 
TABLE 2: SAMPLE SIZE CALCULATIONS .................................................................. 37 
APPENDIX A: COPD ASSESSMENT TESTTM (CAT) ..................................................... 38 
SUMMARY OF AMENDMENTS AND UPDATES .......................................................... 39 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
7 
 
SYNOPSIS 
 
Title: Randomized Pragmatic Clinical Trial in a Community-Based Setting Comparing STIOLTO® 
RESPIMAT® vs. ICS-LABA plus LAMA in Patients with COPD 
Study Name/Brief Title: Assessment In a Real World setting of the effect of Inhaled Steroid-based triple 
therapy versus the combination of tiotropium and olodaterol on reducing chronic obstructive pulmonary 
disease (COPD) Exacerbations [AIRWISE] 
Sponsor: Boehringer Ingelheim 
Treatment: Stiolto® Respimat® 
Active Ingredient: Tiotropium bromide & olodaterol 
Comparator Product: Inhaled Corticosteroid plus Long-acting beta agonists combination plus Long-acting 
muscarinic antagonists (ICS plus LABA plus LAMA)  (Triple Therapy) 
Protocol No.:  1237-0064 
Study Physicians:  Approximately 400 physicians who actively manage adult patients in the target 
indication, chronic obstructive pulmonary disease (COPD).   
Country: United States (US) 
Patients: Adults (40 years of age or older) with COPD who are currently on long-acting muscarinic 
antagonist (LAMA) or long-acting beta agonist (LABA) or inhaled corticosteroid (ICS)/LABA maintenance 
therapy, and whose treatment is not controlled on the current medication regimen as determined by the 
physician. 
Anticipated enrollment for this study is approximately 3200 patients, with approximately 1600 patients 
enrolled in each group. Patients will be randomized to either Stiolto Respimat or ICS plus LABA plus 
LAMA (triple therapy) made up of the combination of any approved drugs that their physician chooses. 
Study Objectives: The objectives of this study are as follows: 
1.) The primary objective of this pragmatic study is to compare the time to first moderate or severe 
COPD exacerbation in patients, not controlled on their current therapy, randomized to Stiolto 
Respimat versus triple therapy over 12 months of treatment. 
2.) The secondary objectives of this study are: 
a. To compare the annual rate of moderate or severe COPD exacerbations for patients on 
Stiolto Respimat with patients on triple therapy. 
b. To compare the time to first severe COPD exacerbation in both treatment arms.  
c. To compare the annual rate of severe COPD exacerbations in both treatment arms. 
d. To compare the proportion of patients with moderate or severe COPD exacerbations in both 
treatment arms. 
 
 
 
 
 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
8 
 
Study Endpoints: 
Primary endpoint: time to first moderate or severe chronic obstructive pulmonary disease (COPD) 
exacerbation over 12 months of treatment 
 
Secondary endpoints: 
• 
Annual rate of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations 
• 
Time to first severe chronic obstructive pulmonary disease (COPD) exacerbation over the 12 
month observation period 
• 
Annual rate of severe chronic obstructive pulmonary disease (COPD) exacerbations 
• 
Proportion of patients with moderate or severe chronic obstructive pulmonary disease (COPD) 
exacerbations over the 12 month observation period 
 
 
 
 
 
 
 
 
Study Design:  This is a pragmatic randomized open label active controlled parallel group design trial 
conducted in a real-world, community-based practice setting for a fixed duration of 12 months of treatment.  
All participating patients will already be on LAMA, LABA or ICS/LABA for COPD, but will have been 
determined by their physician to not be controlled on their current therapy.  Patients enrolled in the study 
will be randomized to either Stiolto Respimat or ICS plus LABA plus LAMA (triple therapy) and provided 
with a prescription for the assigned treatment.   
Inclusion and exclusion criteria are minimally restrictive and there are few study-specific evaluations.  Study 
physicians will follow and treat patients according to their routine clinical practice and judgment.  Clinical 
and healthcare claims data will be collected from study patients for 12 months.  
 
 
 
 
It is anticipated that patients who are being treated for COPD will, as part of usual care, likely undergo 
medical evaluation at regular intervals over the course of the study.  Physicians will collect study data during 
patient office visits and other patient contact (e-mail, phone, contact with another treating physician, receipt 
of records) that occur as part of standard clinical practice over the course of the study.  However, the only 
required study visits are a baseline visit and a final end of study (EOS) visit at 12 months.   
Patient Selection: 
Inclusion Criteria:   
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study: 
Priority will be given to patients actively enrolled in an 
 affiliated health plan. 
• 
COPD diagnosis as defined by the study physician 
• 
Currently on one of the following maintenance therapies: 
o LAMA monotherapy  
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
9 
 
o LABA monotherapy  
o ICS/LABA (Fixed Dose Combination (FDC)) 
• 
Physician determination that patient is not controlled on current pharmacotherapy  
• 
Adult patient 40 years of age or older at time of study enrollment 
• 
Willingness and ability to understand and provide documented Informed Consent Form (ICF) and 
Health Insurance Portability and Accountability Act (HIPAA) Authorization Form prior to 
commencement of any study required assessments, either directly or through Legally Authorized 
Representative. 
Exclusion Criteria: 
Patients presenting with any of the following exclusion criteria will not be eligible for enrollment into the 
study: 
• 
Currently on LAMA/LABA (free or FDC) or triple therapy (ICS plus LABA plus LAMA) 
• 
Contraindication to any study medications (LAMA, LABA or ICS) 
• 
Documented diagnosis of current asthma 
• 
Pregnant or nursing women 
 
Study Procedures: 
• 
Study physicians will identify eligible patients for participation. 
• 
Study physicians will obtain written informed consent and patients will be randomized to either 
Stiolto Respimat or triple therapy upon enrollment. 
• 
Study physicians will collect demographic, clinical and COPD history data on electronic Case 
Report Forms (eCRFs) at baseline. 
• 
A complete blood count (CBC) including differential white cell count will be drawn at baseline. In 
the event that a CBC is not available at baseline, laboratory results within 12 months of baseline will 
be accepted. 
• 
The COPD Assessment TestTM (CAT) symptom score will be assessed at baseline. 
• 
Study physicians will collect patient data (exacerbations, targeted medication changes, selected 
adverse events (AEs) (AEs leading to study treatment discontinuation, dose modification, or trial 
withdrawal)) during any patient office visits or other patient contact during the 12 months the 
patient is on study and enter it via an electronic data capture (EDC) system. Any Serious Adverse 
Events (SAEs), including COPD exacerbation SAEs, will be collected via paper system. 
• 
Clinical data collection at the EOS visit at 12 months will include exacerbations, targeted 
medication changes, selected AEs and any SAEs. 
• 
 
 
 
 
 
Study Duration:  Patients will be on study and followed for 12 months by the physician to collect clinical 
data. 
 
Patient Reported Outcomes (PROs):  The CAT will be administered at baseline to provide a simple and 
reliable measure of health status in COPD and assist patients and their physicians in quantifying the impact 
of COPD on the patient’s health at baseline.   
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
10 
 
Effectiveness Analysis:  The primary effectiveness analysis will assess time to first moderate or severe 
COPD exacerbation (as prospectively collected in the eCRF) of Stiolto Respimat compared to triple therapy.  
A Cox proportional hazards model will be used to compare treatments.   
Secondary/Sensitivity Analyses:  As a secondary effectiveness objective, the annual rate of moderate or 
severe exacerbations will also be calculated and compared between treatment groups.  Other secondary 
analyses include evaluation of severe COPD exacerbations for time to first exacerbation and annual rate, 
proportion of patients with moderate or severe COPD exacerbations, sensitivity analyses relating to 
exacerbation definition and source data, and sensitivity analyses relating to generalizability of the study 
population.   
 
 
 
 
 
Safety:  All SAEs reported by the patients during the study period are required to be documented on the 
appropriate SAE reporting form.  Selected AEs, e.g. AEs leading to study treatment discontinuation, dose 
modification, or trial withdrawal, will be collected on the eCRF during the study. During extraction of data 
from the claims database, any identified SAEs will be reported if not already collected on SAE form. 
 
 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
11 
 
LIST OF ABBREVIATIONS 
 
Abbreviation or 
Special Term 
Definition  
AE 
Adverse Event 
AIRWISE 
Assessment In a Real World setting of the effect of Inhaled 
Steroid-based triple therapy versus the combination of 
tiotropium and olodaterol on reducing COPD Exacerbations 
CAT 
COPD Assessment Test 
CBC 
Complete Blood Count 
eCCGs 
Electronic Case Report Form Completion Guidelines 
CDM 
Clinical Data Manager 
CFR 
Code of Federal Regulations 
CMH 
Cochran-Mantel-Haenszel 
COPD 
Chronic Obstructive Pulmonary Disease 
eCRF 
Electronic Case Report Form 
DMP 
Data Management Plan 
ECG 
Electrocardiogram 
EDC 
Electronic Data Capture 
EMA 
European Medicines Agency 
EOS 
End of Study 
ER 
Emergency Room 
FDA 
Food and Drug Administration 
FDC 
Fixed Dose Combination 
FEV1 
Forced Expiratory Volume in One Second 
FVC 
Forced Vital Capacity 
GOLD 
Global Initiative for Chronic Obstructive Lung Disease 
HCRU 
Healthcare Resource Utilization 
HIPAA 
Health Insurance Portability and Accountability Act 
 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
12 
 
Abbreviation or 
Special Term 
Definition  
HR 
Hazard Ratio 
ICD-10 
International Classification of Disease, 10th Revision 
ICF 
Informed Consent Form 
ICS 
Inhaled Corticosteroid 
ID 
Identifier 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
ISF 
Investigator Site File 
ITT 
Intent to Treat 
LABA 
Long-Acting Beta Agonist 
LAMA 
Long-Acting Muscarinic Antagonist 
MedDRA 
Medical Dictionary for Regulatory Activities 
PP 
Per Protocol 
PRO 
Patient Reported Outcome 
PT 
Preferred Term 
PV 
Pharmacovigilance 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SM 
Service Mark 
SMQ 
Standardized Medical Queries 
SOC 
System Organ Class 
T2DM 
Type 2 Diabetes Mellitus 
TM 
Trademark 
US 
United States 
WISDOM 
Withdrawal of Inhaled Steroids during Optimized 
Bronchodilator Management 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
13 
 
1 
INTRODUCTION 
1.1 
Background and Rationale 
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by 
progressive airflow limitation and airway inflammation leading to a gradual loss in lung 
function.1  COPD is one of the most prevalent chronic diseases and the third leading cause of 
deaths in the United States (US) in 2011.2  However, a majority of the patients (>50%) with low 
pulmonary function are unaware of their COPD condition.3  This under diagnosis poses 
challenges in community clinical practice, resulting in inappropriate patient management. 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends classifying 
patients for treatment based on assessment of existing symptoms, severity of airflow limitation, 
and history of exacerbations.4  Airflow obstruction is measured by spirometry, which is 
considered as the gold standard for accurate and repeatable measurement of lung function.  The 
presence of post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital 
capacity (FVC) <0.70 confirms the presence of persistent airflow limitation and hence COPD 
diagnosis.  However, spirometry is significantly underutilized by primary care physicians to 
confirm the diagnosis of COPD.5   
For patients who are diagnosed with COPD, treatments include maintenance medication with 
mono- and combination bronchodilator therapies.  Treatment with both a long-acting muscarinic 
antagonist (LAMA) and a long-acting beta agonist (LABA) has been recommended in patients 
whose COPD is not sufficiently controlled with mono- bronchodilator therapy.  Clinical trials 
examining combination treatment with LAMA and LABA have shown long term improvements 
in lung function, symptom scores, and exacerbations in patients with moderate to very severe 
COPD.6,7  Further, the convenience of fixed dose combination (FDC) products might provide an 
improved patient-centered approach that enhances patient acceptance and adherence to dual 
                                                        
 
1 Dewar M, Curry W. Chronic Obstructive Pulmonary Disease: Diagnostic Considerations. Am Fam Physician. 
2006 Feb 15;73(4):669-676. 
2 Hoyert DL, Xu JQ. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012; 61(6):1-65. Hyattsville, MD: 
National Center for Health Statistics. 2012 
3 Center for Disease Control and Prevention. What is COPD? Available at http://www.cdc.gov/copd/index.htm. 
Accessed on January 20, 2015. 
4 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) 2017. Available from: http://goldcopd.org. Accessed on March 4, 2017. 
5 Mapel DW, Dalal AA, Johnson P, et al. A clinical study of COPD severity assessment by primary care physicians 
and their patients compared to spirometry. Am J Med. 2015. doi: 10.1016/j.amjmed.2014.12.018. 
6 Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients 
with COPD:  a 6 month study. Respir Med. 2008;102:1511-1520. 
7 Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of 
COPD. COPD. 2009;6:17-25. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
14 
 
bronchodilator therapy and reduces copay burden to the patient.  Stiolto® Respimat® is an FDC 
containing tiotropium (a LAMA) and olodaterol (a LABA) that was approved by the Food and 
Drug Administration (FDA) in May of 2015.  Multiple randomized controlled trials have 
demonstrated that the Stiolto Respimat is superior to either monotherapy. 
GOLD 2017 does not recommend the use of triple combination therapy (LABA/inhaled 
corticosteroid (ICS) + LAMA) except potentially in a subset of patients in group D (high risk for 
exacerbation/high symptom scores).  On the other hand, long-acting bronchodilators, including 
the combination of LAMA and LABA, are recommended as options in groups B (low risk for 
exacerbation/high symptoms scores), C (high risk for exacerbation/low symptoms scores) and D. 
However, multiple observational analyses of real-world data, including the preparatory analyses 
performed by 
 in the 
 population, continue to show a high proportion of 
COPD patients being prescribed ICS-containing regimens, including triple therapy.  The 
magnitude of ICS prescribing seems to be contrary to the recommendations provided by GOLD 
2017, and provides the impetus to perform the proposed study. 
While the benefits of ICS therapy are well documented across a broad spectrum of patients with 
asthma, their benefits in the COPD population appear to be more targeted to select patient 
phenotypes.  Specifically, the benefit appears to be most robust in patients with severe COPD 
with a history of frequent exacerbations or with an inflammatory/allergic component to their 
disease.  In addition, ICS therapy is associated with localized symptoms such as voice hoarseness 
and thrush, as well as systemic diseases such as upper respiratory tract infections and 
osteoporosis. 
The Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management (WISDOM)8 
trial explored the impact of withdrawing ICS in patients concurrently receiving LAMA/LABA 
combination therapy.  In this randomized, double-blind, non-inferiority designed study the risk 
of moderate or severe exacerbations was similar between those who had their ICS withdrawn 
versus those who continued.  A logical follow-up research question from the WISDOM study is 
to assess patients who are not controlled on their current therapy of ICS-LABA, LABA alone or 
LAMA alone, to see if change in therapy to LAMA/LABA FDC therapy is similar in effect to 
triple therapy.  Studying the question in a manner that assesses patients as therapy is “stepped-
up” is reflective of usual clinical practice and would provide valuable and relevant real-world 
evidence to both practicing clinicians and health care payers.  In addition, the GOLD 2017 
update specifically states that “more evidence is needed to draw conclusions on the benefits of 
triple therapy LABA/LAMA/ICS compared to LABA/LAMA.”  To this end, the proposed study, 
AIRWISE: Assessment In a Real World setting of the effect of Inhaled Steroid-based triple 
                                                        
 
8 Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of Inhaled Glucocorticoids and Exacerbations of 
COPD. N Engl J Med. 2014;317:1285-94. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
15 
 
therapy versus the combination of tiotropium and olodaterol on reducing COPD Exacerbations, 
is a non-inferiority trial of community-based COPD patients randomized to either Stiolto 
Respimat or triple therapy following a physician decision to escalate therapy.  The decision to 
escalate therapy will be at the discretion of the treating physician.  Patients will be treated 
according to routine clinical practice and followed for clinical (exacerbations, etc.) 
 
 
 
2 
STUDY OBJECTIVES   
2.1 
Primary Objectives 
The primary objective of this pragmatic study is to compare the time to first moderate or severe 
COPD exacerbation in patients, not controlled on their current therapy, randomized to Stiolto 
Respimat versus triple therapy over 12 months of treatment. 
2.1.1 
Primary Objective Definitions 
For the purpose of this study, a COPD exacerbation is defined as a complex of lower respiratory 
events/symptoms (increase or new onset) related to the underlying COPD, with duration of three 
days or more, requiring a prescription of antibiotics and/or systemic steroids and/or 
hospitalization. 
A complex of lower respiratory events/symptoms is defined as at least two of the following: 
• Shortness of breath 
• Sputum production (volume) 
• Change in sputum color 
• Cough 
• Wheezing 
• Chest tightness 
“Onset of exacerbation” will be defined by the onset of first recorded symptom.  The “end of 
exacerbation” will be decided by the investigator based on clinical judgment. 
Exacerbations will be classified as follows: 
Moderate: Exacerbation requiring receipt of an exacerbation-related prescription of oral 
corticosteroids and/or antibiotic, but not requiring hospitalization 
Severe: Exacerbation requiring COPD-related hospitalization 
For hospitalizations associated with COPD exacerbation, the information collected should 
include the start date of all COPD-related hospitalizations, as well as the discharge date from the 
hospital or equivalent. 
2.2 
Secondary Objectives 
The secondary objectives of this study include: 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
16 
 
1) To compare the annual rate of moderate or severe COPD exacerbations for patients on 
Stiolto Respimat with patients on triple therapy. 
2) To compare the time to first severe COPD exacerbation in both treatment arms.  
3) To compare the annual rate of severe COPD exacerbations in both treatment arms. 
4) To compare the proportion of patients with moderate or severe COPD exacerbations in 
both treatment arms. 
3 
STUDY ENDPOINTS 
The primary endpoint of this study is time to first moderate or severe chronic obstructive 
pulmonary disease (COPD) exacerbation over 12 months of treatment. 
Secondary endpoints include: 
• Annual rate of moderate or severe chronic obstructive pulmonary disease (COPD) 
exacerbations 
• Time to first severe chronic obstructive pulmonary disease  (COPD) exacerbation 
over the 12 month observation period 
• Annual rate of severe chronic obstructive pulmonary disease  (COPD) exacerbations 
• Proportion of patients with moderate or severe chronic obstructive pulmonary disease 
(COPD) exacerbations over the 12 month observation period 
 
 
 
 
 
 
 
 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
17 
 
4 
STUDY DESIGN 
4.1 
Overview 
This is a pragmatic non-inferiority trial conducted in a real-world, community-based practice 
setting for a fixed duration of 12 months of treatment.  All participating patients will already be 
on LAMA, LABA or ICS/LABA for COPD, but will have been determined by their physician to 
not be controlled on their current therapy.  No definition of ‘controlled’ will be offered by the 
trial protocol in order to allow physicians to make real-world autonomous decisions.  Patients 
enrolled in the study will be randomized to either Stiolto Respimat or ICS plus LABA plus 
LAMA (triple therapy) and provided with a prescription for the assigned treatment.  Study 
treatments will be open-label. 
In keeping with the study objective to evaluate Stiolto Respimat in a real-world setting, this 
study is naturalistic in design.  Inclusion and exclusion criteria are minimally restrictive and 
there are few study-specific evaluations.  Study physicians will follow and treat patients 
according to their routine clinical practice and judgment.  Patients who enroll in the study agree 
to the release of health information and to answer questions about their health during the course 
of the study.  Clinical and healthcare claims data will be collected from study patients for 
approximately 12 months.  
 
 
 
 
 
 
 
 
 
Consistent with the naturalistic design, this study does not have a rigid visit schedule.  It is 
anticipated that patients who are being treated for COPD will, as part of usual care, likely 
undergo medical evaluation at regular intervals.  Physicians will collect study data during patient 
office visits and other patient contact (e-mail, phone, contact with another treating physician, 
receipt of records) that occur as part of standard clinical practice over the course of the study.  
The only required study visits are a baseline visit and a final end of study (EOS) visit at 12 
months post enrollment. 
4.2 
Practice and Participant Selection 
4.2.1 Physician Practice Eligibility 
Enrollment of approximately 400 physician sites with an adequate COPD population in the US is 
anticipated. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
18 
 
4.2.2 Participant Recruitment and Eligibility 
Eligible participants include active COPD patients whose physicians determine that their COPD 
is not controlled on their current therapy (LAMA or LABA monotherapy or ICS/LABA).  
Patient recruitment and eligibility study procedures reflect the study’s goal of evaluating Stiolto 
Respimat in a real-world setting.  As such, patients will be recruited from the physician’s patient 
population in a manner that is representative of the real-world population who are currently 
receiving care within their practice. 
The determination that the patient is not controlled on their current therapy, and therefore 
eligible for the study, is at the discretion of the physician.  Once an eligible patient is enrolled, 
they will be randomized in sequence. 
It is anticipated that participants will be recruited from patients who are actively enrolled in an 
 of 
 or 
 health plan (hence forth referred to as 
 health plans).  To 
meet enrollment goals recruitment will allow non-
 patients within enrolled physician 
practices, which may include Medicare/Medicaid patients.  
 
 
4.2.3 Participant Inclusion Criteria 
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the 
study: 
Priority will be given to patients actively enrolled in an 
 affiliated health plan. 
• COPD diagnosis as defined by the study physician 
• Currently on one of the following maintenance therapies: 
o LAMA monotherapy  
o LABA monotherapy  
o ICS/LABA (FDC) 
• Physician determination that patient is not controlled on current pharmacotherapy  
• Adult patient 40 years of age or older at time of study enrollment 
• Willingness and ability to understand and provide documented Informed Consent Form 
(ICF) and Health Insurance Portability and Accountability Act (HIPAA) Authorization 
Form prior to commencement of any study required assessments, either directly or 
through Legally Authorized Representative. 
4.2.4 Participant Exclusion Criteria 
Patients presenting with any of the following exclusion criteria will not be eligible for enrollment 
into the study: 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
19 
 
• Currently on LAMA/LABA (free or FDC) or triple therapy (ICS plus LABA plus LAMA) 
• Contraindication to any study medications (LAMA, LABA or ICS) 
• Documented diagnosis of current asthma 
• Pregnant or nursing women 
Women of childbearing potential are not restricted in this trial, however it is expected that the 
investigator will assess the risks and benefits of the assigned treatment as per the product label(s) 
and discuss this with any women of childbearing potential prior to providing the patient with the 
prescription for the assigned treatment. 
4.2.5 Participant Enrollment 
Anticipated enrollment for this study is approximately 3200 patients, with approximately 1600 
patients enrolled in each group. 
4.2.6 Patient Randomization 
Enrolled study patients will be randomized to either Stiolto Respimat or triple therapy in a 1:1 
ratio.  Once the study physician has determined patient eligibility and has enrolled them into the 
study in the Electronic Data Capture (EDC) system, the physician will receive the randomization 
assignment (Stiolto Respimat or triple therapy) for that patient.   
Patient eligibility and randomization is depicted in the study schematic (Figure 1). 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
20 
 
Figure 1: Schematic of Study Design 
Prior to  
Enrollment 
 
 
 
 
 
Enrollment 
 
 
 
 
 
 
 
 
 
Visit 1 
Time Point  
(Baseline Visit) 
 
 
 
 
 
Regular Care 
(On Study) 
 
 
 
 
 
 
 
 
End of Study 
(12 Month 
Visit) 
 
 
 
 
 
The only required study visits are Baseline and EOS at 12 months.  Data will be collected at 
routine clinical visits and other patient contact in between Baseline and EOS if available per 
standard clinical practice.  See Table 1 for additional detail. 
Screening Procedures 
• 
Identify eligible patients  
• 
Screen potential participants by inclusion and exclusion criteria  
• 
Obtain informed consent 
• 
Document inclusion/exclusion criteria   
Baseline Assessments  
Document:  
• 
Demographics 
• 
COPD history including exacerbations, pre-specified comorbid conditions, 
targeted medications, and reason for therapy escalation 
• 
Smoking status, blood eosinophil results  
• 
COPD Assessment Test (CAT) responses  
Randomize 3200 Participants Total 
Triple Therapy  
1600 participants 
Stiolto Respimat 
1600 participants 
On Study Follow-Up Assessments  
Patients seen according to routine clinical practice and physician judgment. Document:  
• 
Moderate to severe exacerbations, AE leading to discontinuation or dose 
modification of study treatment, or trial withdrawal, and SAEs  
• 
Treatment changes, select medication changes, changes to study medication  
 
Final Assessments 
Document:  
• 
Moderate to severe exacerbations, AE leading to discontinuation or dose 
modification of study treatment, or trial withdrawal, SAEs  
• 
Treatment changes, select medication changes, changes to study medication  
 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
21 
 
5 
STUDY PROCEDURES 
5.1 
Enrollment Procedures 
Once potential physician sites have been identified, physicians who agree to participate in the 
study will be enrolled.  Following Institutional Review Board (IRB) approval of a site and study 
training, sites will begin patient enrollment.  The physician will make the decision regarding the 
patient’s suitability for the study, and in order to maintain the real-world nature of the study, 
patients will be approached for potential enrollment into the study during routine office visits or 
other patient contact as part of their standard care.   
5.2 
Baseline Visit 
Eligible patients interested in participating will provide written informed consent and be 
randomized to either Stiolto Respimat or triple therapy at their baseline visit.  Data collection at 
baseline will include inclusion/exclusion criteria as well as the data outlined in the sections 
below.  A blood sample will be drawn at the baseline visit for a complete blood count (CBC) 
including differential white cell count.  In the event that a CBC is not available at baseline, 
laboratory results within 12 months of baseline will be accepted. 
5.2.1 Participant Characteristics 
Study physicians or trained site personnel will collect patient characteristics at each office visit 
as summarized in Table 1, either directly from the patient or abstracted from the patient’s chart, 
and enter them into the electronic Case Report Form (eCRF).  Baseline assessments will include 
demographic data, baseline clinical data (selected pre-specified comorbid conditions, CBC 
including a required baseline blood eosinophil count, and smoking status) as well as COPD and 
exacerbation history. 
5.2.2 Treatments 
Upon enrollment, patients will be randomized to receive either Stiolto Respimat or triple therapy.  
Treatment details will be recorded in the eCRF. 
5.3 
PROs 
Symptomatology will be assessed at baseline via the COPD Assessment TestTM (CAT) to enable 
classification of patients by the 2017 GOLD A-D criteria in conjunction with exacerbation 
history data.  Patients will complete the CAT and site study personnel will enter the completed 
forms into the eCRFs. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
Protocol No. 1237-0064 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
22 
5.3.1 COPD Assessment Test TM (CAT) 
The CAT is a short (8-item), simple, patient-completed questionnaire that measures the impact of 
COPD on a patient’s well-being and daily life.9  Patients rate the following items on a 6-point (0-
5) scale, where higher scores indicate worse symptoms: Cough, Phlegm, Chest Tightness,
Breathlessness, Activities at Home, Confidence Leaving Home, Sleep and Energy.  Scores from 
individual items are summed, yielding CAT scores ranging from 0-40, with higher scores 
indicating worse COPD-related health status. 
The CAT instrument is attached in Appendix A. 
5.4 
Study Period 
Patients will be followed from baseline to EOS at 12 months.  
 
 
 Patients will be followed for the full 12 months 
regardless of study treatment changes or discontinuation during the study period.  Only if a 
patient withdraws consent will data collection be discontinued. 
Consistent with the naturalistic design, this study does not have a rigid visit schedule.  Patients 
will be followed for 12 months according to their treating physician’s routine clinical practice 
and judgment.  On-study data collection during routine clinical visits or other contacts with 
patient, such as by phone or e-mail, contact with another treating physician, or receipt of records, 
will include exacerbations, COPD targeted concomitant medications, changes to study treatment, 
adverse events (AEs) leading to study treatment discontinuation, dose modification, or trial 
withdrawal and any Serious Adverse Events (SAEs).  It is anticipated that patients who are being 
treated for COPD will undergo medical evaluation at regular intervals; however, the only 
required study visits are baseline and EOS at 12 months. 
The study is anticipated to take 36 months from commencement of enrollment through data 
analysis and reporting. 
5.5 
Final Visit/EOS 
The EOS visit will be 12 months after baseline.  Data collection at EOS will include 
exacerbations, COPD concomitant medications, changes to study treatment, AEs leading to study 
treatment discontinuation or dose modification, or trial withdrawal, and any SAEs.  Post-study 
treatment is at the discretion of the physician. 
The study visit schedule is summarized in Table 1. 
9 Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir 
J. 2009;34:648-654. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
23 
 
5.7 
Withdrawals 
5.7.1 Physician Practices 
Boehringer Ingelheim and/or the IRB reserve the right to terminate the study or participation of 
the study physicians at any time.  In such cases, data collection will end.  After the collected data 
is received, the participating study physicians will be compensated as contractually agreed. 
5.7.2 Participants 
Discontinuation will be based upon physician clinical determination and/or by patient decision.  
Participation in this study is voluntary, and all patients are free to terminate their participation at 
any time.  In the event of early termination of study participation, details regarding the 
discontinuation will be recorded.  Patients will be followed for the full 12 months regardless of 
treatment changes or discontinuation during the study period.  Only if a patient withdraws 
consent will data collection be discontinued.  The study physician will record the reason for 
withdrawal and continue follow-up with the patient for any unresolved SAEs. 
 
6 
STATISTICAL METHODS 
6.1 
Analysis Overview 
This is a randomized, open-label, parallel-group, non-inferiority design pragmatic study, with a 
fixed duration of 12 months.  Patients are randomized to Stiolto Respimat or triple therapy.  The 
primary endpoint is the time to first moderate or severe COPD exacerbation. 
Null hypothesis for non-inferiority 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
24 
 
The null hypothesis of this non-inferiority trial is that the hazard ratio (HR) of time to first 
moderate or severe COPD exacerbations in the Stiolto Respimat arm compared to the triple 
therapy arm is larger than 1.2.  The non-inferiority margin of 20% was based on practical 
considerations and kept consistent with the margin used in the WISDOM study.10  
H0: HR(Stiolto Respimat/Triple Therapy) >= 1.2 
versus 
H1: HR(Stiolto Respimat/Triple Therapy) < 1.2 
This will be addressed by comparing the upper bound of the 95% two-sided confidence interval 
for the HR with the non-inferiority margin of 1.2. 
6.2 
Study Populations 
The following populations will be defined for analysis and reporting. 
6.2.1 Analysis Populations 
6.2.1.1 Intent to Treat (ITT) Population 
The ITT population will include all randomized patients allocated to their original randomized 
treatment group, even if they switched or discontinued study treatment. 
6.2.1.2 Per Protocol (PP) Population 
No per-protocol set is defined and no analysis is planned.  A sensitivity analysis using on-
treatment exacerbations is described in Section 6.4. 
 
 
 
 
 
 
 
6.2.2 Safety Population 
The safety population will include all randomized patients who received a prescription of any 
study treatment (Stiolto Respimat or triple therapy).  
                                                        
 
10 Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of Inhaled Glucocorticoids and Exacerbations of 
COPD. N Engl J Med. 2014;317:1285-94. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
25 
 
6.3 
Sample Size Determination  
6.3.1 Power and Sample Size for Primary Objective 
Table 2 presents several scenarios considered for sample size.  The sample size for this study is 
3200 patients, with 1600 in each treatment group.  This sample size was calculated using 
Addplan 6.1 software based on a non-inferiority test for survival analysis (with Schoenfeld’s 
formula for calculating the number of events), under the following assumptions: 
• Expected HR of moderate or severe COPD exacerbations of 1.0 between Stiolto 
Respimat and triple therapy 
• 20% non-inferiority margin, with HR boundary of 1.20 
• 42.5% of patients in the triple therapy arm have at least one moderate or severe COPD 
exacerbation in 12 months 
• 90% power 
• One-sided Type I error rate of 0.025 
• Randomization ratio 1:1 between treatment arms 
• Fixed trial duration with 12 month follow up 
• 15% drop-out rate during 12 months in both treatment arms 
6.3.2 Randomization and Blinding 
A 
 statistician independent from the study will create the randomization schedule to 
be loaded into the EDC system.  Randomization will be validated by an independent statistician 
for the 3200 sample size plus 25% overrun.  Patients will be randomized in equal ratio to the two 
treatment arms and blocked randomization will be used.  The block size will be documented in 
the study report. 
This is an open-label randomized phase 4 trial, which is designed and conducted as a pragmatic 
trial, i.e. as a study in a real-world setting with minimal inclusion/exclusion criteria and few 
study-specific visits and procedures.  Blinding for this open-label pragmatic trial is not feasible; 
however selection bias will be eliminated via concealed treatment allocation through the EDC 
system.  The database for this pragmatic trial will not be blinded.  
6.3.3 Interim Analysis 
There is no interim analysis planned for this trial. 
6.4 
Effectiveness Analysis 
The effectiveness analysis will address the primary objective of this study: to determine whether 
Stiolto Respimat is non-inferior to triple therapy as measured by time to first moderate or severe 
exacerbation.  For the primary endpoint, COPD exacerbation defined as moderate or severe as 
collected in the eCRF will be used.   
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
26 
 
The primary analysis for the primary endpoint will be performed using the ITT population. 
Patients will be analyzed using the treatment arm to which they are randomized to, even if they 
switched or discontinued study treatment.  Patients will be censored at the time of last contact or 
death, if they did not experience a moderate or severe COPD exacerbation before.  The 
exacerbation data from eCRF will be used for the primary analysis.  
For the primary endpoint, i.e. time to first moderate or severe COPD exacerbation, the Cox 
proportional hazards model with baseline ICS prior use as a covariate will be used to estimate the 
HR and the two-sided 95% Wald confidence interval.  
 
 
 
 
 
The primary endpoint will also be analyzed for moderate or severe COPD exacerbations from 
different data sources: (1) claims data only and (2) integrated eCRF/claims data.  
The details of all analyses will be fully described in the Statistical Analysis Plan (SAP). 
6.5 
Patient Reported Outcome (PRO) Analysis 
The impact of COPD on patients’ health and quality of life will be assessed at baseline via the 
CAT.  PRO analysis will be descriptive in nature and will not involve any statistical testing.  
Rather, summary statistics will be used to describe patient perceived health status impairment 
associated with COPD at baseline, as well as potentially as an explanatory variable in any 
multivariate analyses or in subgroup analyses. 
6.6 
Safety Analysis 
Collection of AEs in the study eCRF will be limited to AEs leading to study treatment 
discontinuation or dose modification, or trial withdrawal.  All SAEs will be reported by the 
investigator via a dedicated SAE report form directly to Boehringer Ingelheim Global 
Pharmacovigilance as described in section 7.2.  As hospitalization SAEs are reflected in claims 
records, a patient-level review comparing hospitalization claims entries with reported SAEs for 
each respective patient will take place after completion of the 12-month visit in order to identify 
any hospitalizations of which the investigator was potentially unaware.  The investigator will 
receive information of any SAE identified through this process and report it using the standard 
SAE reporting process (See section 7.2).    
SAE data for analysis will be drawn from the Boehringer Ingelheim Safety Database. 
Analysis of non-serious AEs (leading to study treatment discontinuation or dose modification, or 
trial withdrawal) will be performed on the study database, as these are entered in the eCRF only.  
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
27 
 
Safety analyses will be descriptive in nature.  No hypothesis testing is planned prospectively. 
AEs will be coded using the current version of the Medical Dictionary for Regulatory Activities 
(MedDRA) coding dictionary at the time of reporting, and recoded to the MedDRA version 
current at the time of database integration.  Summary tables and listings will be produced to 
compare the incidence of AEs across treatment groups, by Preferred Term (PT)/System Organ 
Class (SOC) and also by medical concept (MedDRA Standardized Medical Queries (SMQ) or 
custom Boehringer Ingelheim searches termed Pharmacovigilance (PV) endpoints).  All AEs 
with an onset after the first dose of trial medication and up to 21 days after the last dose of trial 
medication will be assigned to the on-treatment period.  Other AEs will be assigned either to the 
screening period, post-treatment period or the post-study period as appropriate. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
28 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
29 
 
6.8 
Missing Data 
Missing data for exacerbation endpoints will not be imputed. 
 
7 
AE REPORTING  
The study physician is responsible for monitoring the safety of participating patients.  All SAEs 
reported by the patients during the study period are required to be documented on the appropriate 
SAE reporting form.  Selected AEs, e.g. AEs leading to study treatment discontinuation, dose 
modification, or trial withdrawal, will also be collected on the eCRF during the study.  SAEs 
identified in patient-level review of hospitalization data extracted from claims will be notified to 
the investigators and then reported by these on the SAE reporting form (cf. section 6.6). 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
30 
 
7.1 
AEs 
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a medicinal product and which does not necessarily have to have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom or disease temporally associated with the 
use of a medicinal product, whether or not considered related to the medicinal product. 
Only selected non-serious AEs will be collected in eCRF: events leading to study treatment 
discontinuation, dose modification, or trial withdrawal. 
Causal relationship of AEs 
Medical judgment should be used to determine the relationship, considering all relevant factors, 
including pattern of reaction, temporal relationship, de-challenge or re-challenge, confounding 
factors such as concomitant medication, concomitant diseases and relevant history. 
Arguments that may suggest a reasonable causal relationship could be: 
• The event is consistent with the known pharmacology of the drug.  
• The event is known to be caused by or attributed to the drug class. 
• A plausible time to onset of the event relative to the time of drug exposure. 
• Evidence that the event is reproducible when the drug is re-introduced. 
• No medically sound alternative etiologies that could explain the event (e.g. preexisting 
or concomitant diseases, or co-medications). 
• The event is typically drug-related and infrequent in the general population not 
exposed to drugs (e.g. Stevens-Johnson syndrome). 
• An indication of dose-response (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is diminished). 
 
Arguments that may suggest that there is no reasonable possibility of a causal relationship 
could be: 
• No plausible time to onset of the event relative to the time of drug exposure is evident 
(e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days/weeks of 
drug administration; an allergic reaction weeks after discontinuation of the drug 
concerned). 
• Continuation of the event despite the withdrawal of the medication, taking into account 
the pharmacological properties of the compound (e.g. after 5 half-lives). 
Of note, this criterion may not be applicable to events whose time course is prolonged 
despite removing the original trigger. 
• Additional arguments amongst those stated before, like alternative explanation (e.g. 
situations where other drugs or underlying diseases appear to provide a more likely 
explanation for the observed event than the drug concerned). 
• Disappearance of the event even though the study drug treatment continues or remains 
unchanged. 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
31 
 
7.2 
SAEs 
A SAE is defined as any AE which fulfils at least one of the following criteria: 
• Results in death 
• Is life-threatening, which refers to an event in which the patient was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused 
death if more severe 
• Requires inpatient hospitalization, or 
• Requires prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity, or 
• Is a congenital anomaly or birth defect, or 
• Is deemed serious for any other reason if it is an important medical event when based on 
appropriate medical judgment which may jeopardize the patient and may require medical 
or surgical intervention to prevent one of the other outcomes listed in the above 
definitions.  
AEs considered “Always Serious” 
In accordance with the European Medicines Agency (EMA) initiative on Important Medical 
Events, Boehringer Ingelheim has set up a list of further AEs, which by their nature, can always 
be considered to be “serious” even though they may not have met the criteria of an SAE as given 
above.  The investigators will be notified of any AE that is entered in the eCRF that meets 
criteria as an Important Medical Event per Always Serious List.  The investigator will promptly 
complete the SAE form with all available information about the AE(s) and report to the 
sponsor’s unique entry point as described in the Investigator Site File (ISF) immediately (within 
24 hours). 
All SAEs will be reported via Boehringer Ingelheim SAE reporting forms to the Global 
Pharmacovigilance Database.  If patient-level review of claims versus site entries reveals any 
hospitalization SAE in claims not already captured by the investigator, the investigator will be 
contacted providing information and asking for completion of an SAE form with those details 
known to him/her.  
7.2.1 Reporting Period of SAEs 
AEs and SAEs will be reported from the time a patient signs consent until the final visit at 12 
months or until the patient discontinues the trial.  After the patient completes or discontinues the 
trial, the investigator does not need to actively monitor the patient for AEs but should only report 
related SAEs of which the investigator may become aware of by any means of contact with the 
patient, e.g. phone call. 
SAE reporting procedure will follow usual Boehringer Ingelheim forms and processes and will 
be further described in the ISF.  The investigator must report SAEs on a Boehringer Ingelheim 
SAE form via the fax form immediately (within 24 hours of investigator’s awareness of the 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
32 
 
event) as described in the ISF.  The same timeline applies if follow up information becomes 
available.   
Healthcare Claims Database SAE reporting process 
If patient level review of claims database versus site entries at‘12+3 month mark’ (3 months after 
the 12 month follow-up visit) reveals any hospitalization in claims database that is not already 
captured by the investigator as an SAE, the investigator will be contacted with this information. 
The investigator will promptly complete the SAE form with all available information about the 
patient’s hospitalization and report to the sponsor’s unique entry point as described in the ISF 
immediately (within 24 hours). 
Information required 
For each AE, the Investigator should provide the information requested on the appropriate eCRF 
pages (if applicable) and Boehringer Ingelheim SAE Report form. The Investigator should 
determine the causal relationship to the trial medication. 
The following should also be recorded as S(AE) in the eCRF and SAE form (if applicable): 
• Worsening of pre-existing conditions,  
• Changes in vital signs, electrocardiograms (ECGs), physical examinations, and laboratory 
test results, if they are judged clinically relevant by the Investigator.  
If such abnormalities already pre-exist prior to trial inclusion they will be considered as baseline 
conditions. 
7.3 
 Pregnancy 
Once a female subject has been enrolled into the trial, after having taken study medication, the 
investigator must report immediately any drug exposure during pregnancy.  Drug exposure 
during pregnancy has to be reported immediately (within 24 hours or next business day, 
whichever is shorter, of the pregnancy becoming known to the investigator) to the defined 
unique entry point for SAE forms by means of Pregnancy Monitoring Form A (pregnancy 
monitoring forms and contact details will be provided in the ISF). 
The outcome of the pregnancy associated with the drug exposure must be followed up and 
reported by means of Pregnancy Monitoring Form B.   
In the absence of an (S)AE, only the Pregnancy Monitoring Form for Clinical Trials and not the 
SAE form is to be completed. 
 
8 
DATA COLLECTION 
8.1 
Data Sources 
Data sources include demographic and clinical data collected prospectively by study sites, 
patient-completed PRO data and administrative claims data from patients on 
 health 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
33 
 
plans (
 and targeted non-
 health plans.  In order to maintain patient 
confidentiality, each patient will be assigned a unique patient study ID upon enrollment to use in 
place of patient name or any other identifying information (e.g., medical record number).  
Clinical study data, PROs and claims-derived variables will be integrated into one analysis 
dataset via this confidential patient ID. 
The study physician has the ultimate responsibility for the collection and reporting of all clinical 
and patient data through the eCRFs as well as ensuring that they are accurate and complete. 
8.2 
eCRFs/EDC 
All clinical study data will be collected at the physician office and entered into eCRF by trained 
site study personnel through a fully validated, 21 CFR 11 and HIPAA compliant EDC system.  
Patients will complete PRO questionnaires (i.e., CAT) by paper and pen and the site study 
personnel will enter the completed forms into the EDC system. 
All study personnel involved in data entry will be trained on patient confidentiality and the EDC 
system prior to beginning data entry.  Site users will be provided eCRF Completion Guidelines 
(eCCGs) to assist with study data collection and entry.  Study personnel will access the EDC 
system through a secure study website. 
8.3 
Database Development 
All prospectively collected study data will reside in a 21 CFR 11 and HIPAA compliant secure 
database, developed and managed by 
 EDC vendor.  Patient-level study data will be 
downloaded from the EDC system to secure 
 servers for linkage to claims derived 
variables via a unique patient ID. 
A Clinical Data Manager (CDM) will manage the study database and act as the system 
administrator, creating and maintaining users and database access privileges.  Standard user-type 
privileges will be configured and implemented to ensure privacy and security compliance policy 
requirements.  Patient confidentiality will be strictly maintained. 
A Data Management Plan (DMP) will be developed at the beginning of the study to describe all 
functions, processes and specifications for collection, cleaning and validation of study data from 
study start up to database lock.   
8.4 
Data Quality Assurance 
The DMP will describe structures, processes, policies and procedures employed to ascertain the 
quality of the data and to ensure against errors in data entry, transfer or transformation accuracy 
throughout the study.  Data quality oversight will involve a multi-tiered process that includes 
electronic edit check specifications, manual checks, self-evident corrections, listing reviews and 
electronic data transfer agreement summaries.  Electronic edit checks will be programmed to 
show discrepancies online at the time of data entry, giving the operator the option to confirm 
acceptance of the discrepant data or change the data.  Manual review and listing reviews will be 
run as outlined in the DMP, either at predetermined intervals or as necessary.  The CDM will 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
34 
 
open queries to resolve any discrepancies either within the database or directly with study 
personnel.  All changes to existing data will be fully tracked, maintaining an audit trail report of 
every transaction. 
 
9 
STUDY MANAGEMENT 
9.1 
Regulatory and Ethical Consideration 
All study activities will be conducted in accordance with regulatory guidelines for real-world, 
pragmatic research.  Study personnel at physician sites will be provided training on the study 
protocol, the ICF, data collection and data entry to ensure both the protection of potential study 
patients as well as the scientific integrity of the study.  A hybrid approach of both remote and 
onsite monitoring will be employed. 
9.1.1 IRB/Independent Ethics Committee (IEC) 
The study physician will have prospective approval of the study protocol, ICF and any patient 
information or recruiting materials, if applicable, prior to commencement of any study activities. 
In the case of a protocol amendment, the study physician must sign the revised protocol and 
submit the amendment to the IRB/IEC for review and approval prior to implementation of any 
changes specified in the protocol amendment.  All changes in research activity and all 
unanticipated problems involving risk to human patients or others must be reported promptly to 
the IRB/IEC. 
The study physician will obtain continued review of the study at intervals not to exceed one year 
or otherwise specified by the IRB/IEC. 
9.1.2 Informed Consent 
An ICF fully describing the purpose, procedures and potential risks and benefits of the study will 
be developed and approved by the IRB/IEC prior to study initiation.  The study physician must 
ensure that each study patient is fully informed of the study and authorizes release of health 
information prior to study enrollment.  The study physician, or study personnel designated by the 
study physician, will obtain written informed consent from each patient prior to initiation of any 
study-related procedures.  Each patient will be given a copy of the signed ICF.  The study 
physician will retain the original signed ICF for each patient. 
The IRB/IEC must prospectively approve the ICF and any changes to the ICF during the course 
of the study before use.  If a protocol amendment alters the study design or increases the 
potential risk to the patient, the ICF must be revised and submitted to the IRB/IEC for review 
and approval prior to implementation.  The revised ICF must then be used to obtain consent from 
new patients entering the study.  The revised ICF must also be used to obtain consent from 
currently enrolled patients if they are affected by the amendment. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
35 
 
9.2 
Dropouts 
Patient participation is strictly voluntary and patients may refuse to participate or withdraw from 
the study at any time and for any reason.  As such, patients may voluntarily withdraw prior to 
completing the final visit.  In such cases, the study physician will document the specific reason 
for the incomplete information (e.g., withdrawal of consent, lost to follow-up) on the eCRF.  The 
physician should continue follow-up with the patient for any unresolved SAEs. 
9.3 
Record Retention and Access 
This study may be subject to audits or evaluations by regulatory authorities or Boehringer 
Ingelheim (or its designee).  To enable such evaluations and/or audits, the study physician must 
agree to maintain and allow reasonable access to required patient and study records.  The study 
physician agrees to keep the identity of all participating patients (sufficient information to link 
records, e.g., hospital records), all original signed ICFs, SAE Forms, source documents, and 
detailed records of treatment disposition, and adequate documentation of relevant 
correspondence (e.g., letters, meeting minutes, telephone calls, reports).  The study physician 
should retain records according to local regulations, or as specified in the Clinical Study 
Agreement, whichever is longer. 
 
10 
PUBLICATION OF STUDY RESULTS 
All information related to this study is considered confidential information belonging to 
Boehringer Ingelheim and 
  A final study report will be generated following 
completion of data collection and analysis.  Results and findings will be submitted to 
conferences and for publication in peer-reviewed scientific journals. 
 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
36 
 
Table 1: Time and Events Schedule 
 
Study Visits 
Assessment or Procedure 
Baseline 
On Study 
Follow-Up1 
EOS 
12 Months 
Written Informed Consent 
X 
 
 
Eligibility Criteria 
X 
 
 
Randomization 
X 
 
 
Demographics 
X 
 
 
Selected pre-specified comorbid 
conditions 
X 
 
 
CBC (Baseline Blood 
Eosinophil Count Required)2 
X 
 
 
Smoking Status 
X 
 
 
COPD Diagnosis Date  
X 
 
 
COPD Exacerbation History 
(number and severity of 
exacerbations in last year) 
X 
 
 
Pre-Study COPD Therapy 
X 
 
 
Reason for therapy escalation 
X 
 
 
COPD Concomitant 
Medications  
X 
X 
X 
CATTM 
X 
 
 
Study Treatment 
X 
X 
X 
COPD Exacerbations 
 
X 
X 
Selected AEs3 
 
X 
X 
SAEs3 
 
X 
X 
1The only required study visits are Baseline and EOS.  Data will be collected at routine clinical 
visits and other patient contact in between Baseline and EOS if available per standard clinical 
practice. 
2In the event that a CBC is not available at baseline, laboratory results within 12 months of 
baseline will be accepted. 
3All SAEs and selected AEs will be collected from Baseline through EOS or early termination of 
study participation.  Selected AEs are AEs leading to study treatment discontinuation, dose 
modification or trial withdrawal. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
37 
 
Table 2: Sample size calculations (with number of events) under different assumptions for 
p1, HR and power, 20% non-inferiority margin, one-sided alpha 0.025 and 15% drop-out 
rate during 12 months. 
Scenario 
P1 (proportion 
of patients with 
>=1 moderate 
/severe COPD 
exacerbation 
during 12 
months in 
Triple Therapy 
arm) 
P2 (proportion 
of patients 
with >=1 
moderate/ 
severe COPD 
exacerbation 
during 12 
months in 
Stiolto arm) 
Expected HR 
of moderate/ 
severe COPD 
exacerbations 
between 
Stiolto and 
Triple 
Therapy 
Power 
Number of 
events 
(moderate/ 
severe COPD 
exacerbations) 
Sample 
size 
(total) 
1 
40% 
39.07% 
0.97 
95% 
1147 
3120 
2 
42.5% 
42.5% 
1 
90% 
1264 
3200 
3 
45% 
46% 
1.03 
80% 
1358 
3204 
These sample size calculations were completed using Addplan 6.1 software based on a non-
inferiority test for survival analysis. 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
38 
 
APPENDIX A: COPD Assessment TestTM (CAT) 
 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
39 
 
 Summary of Amendments and Updates 
 
Summary of Changes 
1237-0064 Protocol Version 2.0, dated 09May2018 
 
Number 
Section/Page 
 
Change 
Rationale 
1 
Global Change 
 
May 9, 2018June 7, 2017 
 
Version 12.0 
 
Updated protocol date and 
version. 
2 
Study Approvals, 
page 2 
Sponsor Approval: 
 
Name:
 
 
Title:  
 of 
Clinical Development & 
Medical 
Affairs, Primary Care - 
RespiratoryCOPD & 
Asthma 
 
 
Updated sponsor Principal 
Investigator for study 
approval signature. 
3 
Synopsis Study 
Procedures, page 9 
 
• A complete blood count 
(CBC) including differential 
white cell count will be 
drawn at baseline. In the 
event that a CBC is not 
available at baseline, 
laboratory results within 12 
months of baseline will be 
accepted. 
 
Added language to relax the 
timing required for a baseline 
CBC. This change increases 
the flexibility of study 
requirements and is 
consistent with the pragmatic 
design. 
4 
Section 4 Study 
Design 
4.2.2 Participant 
Recruitment and 
Eligibility, page 
17-18 
To maintain the real-world 
nature of the study, patients will 
be recruited for enrollment 
when they interact with their 
physician as part of their 
standard care. 
 
Removed sentence to allow 
additional patient outreach at 
study sites to increase study 
enrollment. 
5 
Section 4 Study 
Design 
To enhance enrollment at trial 
initiation, up to 500 non-
 
Deleted sentences to remove 
any restriction from 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
40 
 
4.2.2 Participant 
Recruitment and 
Eligibility, page 18 
patients will be allowed to 
enroll, following which 
enrollment will be restricted to 
 patients only if 
possible.  In such event that 
additional non-
 patients 
are needed to complete 
enrollment, the decision to re-
open enrollment to non-
 
patients will be made jointly 
between 
 and 
Boehringer Ingelheim. 
 
enrollment of non-
 
patients to increase study 
enrollment. 
6 
Figure 1: 
Schematic of 
Study Design, 
page 20 
• Identify Eeligible 
patients interacts with 
physician in course of 
normal care 
Modified sentence to allow 
additional patient outreach at 
study sites to increase study 
enrollment, consistent with 
change #4 in 4.2.2 above 
 
7 
Section 5 Study 
Procedures 
5.2 Baseline Visit, 
page 21 
A blood sample will be drawn 
at the baseline visit for a 
complete blood count (CBC) 
including differential white cell 
count.  In the event that a CBC 
is not available at baseline, 
laboratory results within 12 
months of baseline will be 
accepted. 
 
Added language to relax the 
timing required for a baseline 
CBC. This change increases 
the flexibility of study 
requirements and is 
consistent with the pragmatic 
design. 
8 
Table 1: Time and 
Events Schedule, 
page 36 
 
CBC (Baseline Blood 
Eosinophil Count Required)2 
 
2In the event that a CBC is not 
available at baseline, laboratory 
results within 12 months of 
baseline will be accepted. 
 
Added footnote to relax the 
timing required for a baseline 
CBC. This change increases 
the flexibility of study 
requirements and is 
consistent with the pragmatic 
design, and consistent with 
changes #3 and #7 in Study 
Procedures above. 
 
9 
Table 1: Time and 
Events Schedule, 
page 36 
 
Selected AEs23 
SAEs23 
 
23All SAEs and selected AEs 
will be collected from Baseline 
through EOS or early 
termination of study 
Updated footnote numbering 
to accommodate addition of 
footnote in change #8. 
Doc. No.: c23740530-01


Boehringer Ingelheim 
 
Protocol No. 1237-0064 
 
Version 2.0 May 9, 2018 
CONFIDENTIAL 
41 
 
participation.  Selected AEs are 
AEs leading to study treatment 
discontinuation, dose 
modification or trial 
withdrawal. 
 
 
 
Doc. No.: c23740530-01


 
 
 
 
APPROVAL / SIGNATURE PAGE 
 
Document Number: 
 
Technical Version Number:
 
Document Name: 
 
 
 
                                                                                                                 
 
Title: 
 
 
 
 
                                                                                                                   
 
Signatures (obtained electronically) 
 
Meaning of Signature  
Signed by 
Date Signed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c23740530
1.0
clinical-trial-protocol-version-2
Randomized Pragmatic Clinical in Trial in a Community-Based Setting Comparing
STIOLTO RESPIMAT vs. ICS-LABA plus LAMA in Patients with COPD   The
AIRWISE Study: Assessment In a Real World setting of the effect of Inhaled Steroid
based triple therapy versus the combination of tiotropium and olodaterol on reducing
COPD Exacerbations
Author-Clinical Monitor
08 Jun 2018 12:41 CEST


Boehringer Ingelheim 
Page 2 of 2
Document Number: 
 Technical Version Number:
 
 
 
(Continued) Signatures (obtained electronically) 
 
Meaning of Signature  
Signed by 
Date Signed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c23740530
1.0

SAP_001.pdf: 
Statistical Analysis Plan for Randomized Pragmatic Clinical Trial in a 
Community-Based Setting Comparing STIOLTO® RESPIMAT® vs. ICS-LABA 
plus LAMA in Patients with COPD 
SAP No.  1237-0064 
Fax: 
March 2021 
Version 3.0 
This document and its contents are the property of Boehringer Ingelheim and are 
confidential.  Unauthorized copying or use is prohibited. 
16.


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
2
Signature Page for Statistical Analysis Plan 
SAP No: 1237-0064 
March 2021 
 
 
. Approval: 
 
Name:
 
Title:   Senior Biostatistician 
 
 
 
 
 
 
Signature:   
 
 
 
 
 
 
Date:  
 
 
 
 
Name:
 
Title:   Principal Scientist 
 
 
 
 
 
 
Signature:   
 
 
 
 
 
 
Date:  
 
 
 
 
 
Boehringer Ingelheim Approval: 
 
Name:
 
Title:   Principal Statistician 
           
 
 
 
Signature:   
 
 
 
 
 
 
Date:  
 
 
 
 
Name:
 
Title:   Senior Associate 
 
 
 
 
 
Signature:   
 
 
 
 
 
 
Date:  
 
 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
3
  
TABLE OF CONTENTS 
Signature Page for Statistical Analysis Plan .............................................................................. 2 
TABLE OF CONTENTS ............................................................................................................. 3 
List of Abbreviations .................................................................................................................... 5 
1.0 
INTRODUCTION............................................................................................................. 7 
2.0 
STUDY OBJECTIVES ..................................................................................................... 7 
2.1 
Changes in the Planned Analysis of the Study ........................................................................ 7 
3.0 
STUDY INVESTIGATIONAL PLAN ............................................................................ 8 
3.1 
Patient Randomization .............................................................................................................. 8 
3.2 
Evaluation Schedule and Definitions ....................................................................................... 8 
3.2.1 
Baseline ................................................................................................................................... 9 
3.2.2 
On Study Visits ....................................................................................................................... 9 
3.2.3 
EOS ......................................................................................................................................... 9 
4.0 
STATISTICAL METHODOLOGY................................................................................ 9 
4.1 
General Considerations ............................................................................................................. 9 
4.2 
Sample Size Determination ..................................................................................................... 10 
4.3 
Missing Data ............................................................................................................................. 10 
4.4 
Data Definitions and Calculations .......................................................................................... 10 
4.4.1 
Demographics ....................................................................................................................... 10 
4.4.2 
Treatment Variables .............................................................................................................. 10 
4.4.3 
CAT ....................................................................................................................................... 13 
4.4.3.1 Overview ............................................................................................................................... 13 
4.4.3.2 Scoring and Categorization ................................................................................................... 14 
4.4.3.3 Missing Data ......................................................................................................................... 14 
4.4.4 
COPD and Exacerbation History .......................................................................................... 14 
4.4.5 
GOLD A-D Classification ..................................................................................................... 15 
4.4.6 
Baseline ICS Prior Use .......................................................................................................... 15 
4.4.7 
Blood Eosinophils ................................................................................................................. 15 
4.4.8 
High Risk Classification........................................................................................................ 15 
4.5 
Analysis Assessments ............................................................................................................... 15 
4.5.1 
Primary Endpoint Assessment .............................................................................................. 15 
4.5.2 
Secondary Endpoint Assessments ......................................................................................... 16 
 
 
 
 
 
 
 
 
5.0 
STATISTICAL ANALYSES ......................................................................................... 21 
5.1 
Analysis Populations ............................................................................................................... 21 
5.1.1 
Intent to Treat (ITT) Population ............................................................................................ 21 
5.1.2 
Per Protocol (PP) Population................................................................................................. 21 
 
 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
4
5.1.4 
Safety Population .................................................................................................................. 22 
5.2 
Patient Disposition and Accountability ................................................................................. 22 
5.3 
Demographics and Baseline Clinical Characteristics ........................................................... 22 
5.4 
Treatment Regimen ................................................................................................................. 22 
5.5 
Effectiveness Analysis.............................................................................................................. 23 
5.5.1 
Primary ITT Analysis ............................................................................................................ 23 
 
 
5.5.3 
Secondary Analyses .............................................................................................................. 24 
5.5.3.1 Annual Rate of Moderate or Severe Exacerbations .............................................................. 24 
5.5.3.2 Time to First Severe Exacerbation ........................................................................................ 24 
5.5.3.3 Annual Rate of Severe Exacerbations ................................................................................... 25 
5.5.3.4 Proportion of Patients with Moderate or Severe Exacerbations ............................................ 25 
5.6 
Patient Reported Outcome (PRO) Analysis .......................................................................... 25 
5.7 
Concomitant Medications ....................................................................................................... 25 
6.0 
SAFETY ........................................................................................................................... 34 
6.1 
AEs ............................................................................................................................................ 34 
6.2 
SAEs .......................................................................................................................................... 34 
6.3 
Reporting and Analysis Periods ............................................................................................. 34 
6.4 
Analysis ..................................................................................................................................... 34 
6.4.1 
AE Analysis .......................................................................................................................... 34 
7.0 
IMPORTANT PROTOCOL VIOLATIONS (IPVs) ................................................... 35 
8.0 
APPENDIX A: Randomization Development and Validation.................................... 35 
9.0 
APPENDIX B: COPD Medication Categorization List .............................................. 36 
11.0 
APPENDIX C: COPD Assessment TestTM (CAT) ....................................................... 39 
 
 
 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
5
List of Abbreviations 
 
Abbreviation or 
Special Term 
Definition  
AE 
Adverse Event 
 
 
AIRWISE 
Assessment In a Real World setting of the effect of Inhaled 
Steroid-based triple therapy versus the combination of 
tiotropium and olodaterol on reducing COPD Exacerbations 
CAT 
COPD Assessment Test 
CBC 
Complete Blood Count 
 
 
CI 
Confidence Interval 
CMH 
Cochran-Mantel-Haenszel 
COPD 
Chronic Obstructive Pulmonary Disease 
eCRF 
Electronic Case Report Form 
EDC 
Electronic Data Capture 
E&M 
Evaluation and Management 
EOS 
End of Study 
ER 
Emergency Room 
FDC 
Fixed Dose Combination 
GERD 
Gastroesophageal Reflux Disease 
GLM 
General Linear Model 
GOLD 
Global Initiative for Chronic Obstructive Lung Disease 
 
 
 
 
HR 
Hazard Ratio 
ICD-10 
International Classification of Diseases, Tenth Revision 
ICD-10-CM 
International Classification of Diseases, Tenth Revision, 
Clinical Modification 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
6
Abbreviation or 
Special Term 
Definition  
ICS 
Inhaled Corticosteroid 
IPV 
Important Protocol Violations 
IQR 
Interquartile Range 
ITT 
Intent to Treat 
LABA 
Long-Acting Beta Agonist 
LAMA 
Long-Acting Muscarinic Antagonist 
LOS 
Length of Stay 
MedDRA 
Medical Dictionary for Regulatory Activities 
OCS 
Oral Corticosteroid 
OV 
Office Visit 
PDE4 
Phosphodiesterase 4 
PP 
Per Protocol 
 
 
 
 
PT 
Preferred Term 
RR 
Risk Ratio 
SABA 
Short-Acting Beta Agonist 
SAE 
Serious Adverse Event 
SAMA 
Short-Acting Muscarinic Antagonist 
SAP 
Statistical Analysis Plan 
SD 
Standard Deviation 
SM 
Service Mark 
SMQ 
Standardized Medical Queries 
SOC 
System Organ Class 
T1DM 
Type 1 Diabetes Mellitus 
T2DM 
Type 2 Diabetes Mellitus 
TM 
Trademark 
 
 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
7
1.0 INTRODUCTION 
The background and rationale for this study can be found in the introduction to the study 
protocol (Section 1). 
2.0 STUDY OBJECTIVES 
The primary, secondary 
 
Section 2, Study Objectives).                                                                                       
2.1 Changes in the Planned Analysis of the Study 
Due to slower than expected enrollment despite mitigation efforts, a business decision was made 
to discontinue enrollment of new patients in the trial after the end of August 2019. Active 
patients will continue and any patient that is already randomized into the trial shall continue 
through the planned 12 months of the trial. 
As a result of this early stopping and the limited sample size enrolled by the end of August 2019 
(approximately 703 patients instead of the planned 3200 patients), the trial will be 
underpowered, therefore the null hypothesis of non-inferiority of Stiolto Respimat to Triple 
therapy as measured by time to first moderate or severe exacerbation will not be tested. No 
statistical inference will be done (i.e., no comparison with the NI margin, no calculation of p-
value).  Models, such as the Cox proportional hazards model and the negative binomial, will still 
be run on the ITT population to estimate the hazard ratio, rate ratio and confidence intervals.  
Some changes were made to the thresholds for baseline blood eosinophil level, in sections 4.4.7, 
4.4.8, 4.5.4.3 and 5.5.1, to reflect current GOLD recommendations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
8
 
 
 
 
 
 
 
  
 
 
After further review, due to the low number of patients and events, and the strong knowledge 
base Boehringer Ingelheim (BI) have for Stiolto, the safety team decided that the additional 
custom Boehringer Ingelheim searches which are standardized for relevant topics in COPD 
studies are optional. Therefore the following analyses will not be performed in Section 6.4.1: 
summary tables and listings to compare the incidence of AEs across treatment groups by medical 
concept (MedDRA Standardized Medical Queries (SMQ) or custom Boehringer Ingelheim 
searches which are standardized for relevant topics in COPD studies. 
   
 
 
 
 
 
 
3.0 STUDY INVESTIGATIONAL PLAN 
The details of the study design, AIRWISE: Assessment In a Real World setting of the effect of 
Inhaled Steroid-based triple therapy versus the combination of tiotropium and olodaterol on 
reducing chronic obstructive pulmonary disease (COPD) Exacerbations, are fully described in 
the study protocol (Section 4, Study Design). 
3.1 Patient Randomization 
Enrolled study patients will be randomized to either Stiolto Respimat or triple therapy in a 1:1 
ratio.  Development and validation of the randomization process is described in Appendix A. 
3.2 Evaluation Schedule and Definitions 
Consistent with the naturistic design, this study does not have a rigid visit schedule.  It is 
anticipated that participating patients will undergo medical evaluation at regular intervals as part 
of standard clinical practice.  However, the only required study visits are a baseline visit and a 
final end of study (EOS) visit at 12 months post enrollment. 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
9
3.2.1 Baseline 
Baseline is defined as the first study visit date.  After eligible patients interested in participating 
provide written informed consent, they will be randomized to either Stiolto Respimat or triple 
therapy.  A blood sample will be drawn at the baseline visit for a complete blood count (CBC) 
including differential white cell count or historical CBC can be used if available.  Additionally, 
participating patients will complete the COPD Assessment TestTM (CAT).  The following data 
will be collected at baseline and recorded in the electronic Case Report Form (eCRF): eligibility 
criteria, demographics, selected pre-specified comorbid conditions, COPD history (diagnosis 
date, number of moderate and severe COPD exacerbations in the 12 months prior to study 
enrollment, pre-study COPD therapy, selected pre-specified COPD concomitant medications and 
reason for therapy escalation), blood eosinophil count, smoking status, CAT responses and study 
treatment. 
3.2.2 On Study Visits 
While there are no required on study visits, it is anticipated that patients who are being treated 
for COPD will undergo medical evaluation at regular intervals.  On study data collection will 
occur as patients are followed according to their treating physician’s routine clinical practice and 
judgment for the 12 month study period, including routine clinical visits, other patient contact 
(e.g., phone or e-mail), contact with another treating physician, or receipt of records.  Data 
collected will include COPD exacerbations, selected pre-specified COPD concomitant 
medications, changes to study treatment, adverse events (AEs) leading to study treatment 
discontinuation, dose modification or trial withdrawal, and any serious adverse events (SAEs).  
Patients will be followed and data will be collected at each contact for the full 12 month study 
period regardless of study treatment changes or discontinuation during the study period. 
3.2.3 EOS 
The planned EOS visit will be 12 months after baseline. Data collection at EOS will include 
COPD exacerbations, selected pre-specified COPD concomitant medications, changes to study 
treatment, AEs leading to study treatment discontinuation, dose modification or trial withdrawal, 
and any SAEs. For the purposes of analysis, EOS visits up to 12 months (+30 days) post-
Baseline will be included. EOS visits that occur after this window will be considered for 
inclusion in analysis on a case by case basis.  However, only COPD exacerbations with an onset 
date up to and including 12 months post-Baseline will be included in analysis. 
 
4.0 STATISTICAL METHODOLOGY 
4.1 General Considerations 
Statistical programming and analyses will be performed using SAS® version 9.4 or higher.  
Some analyses will utilize prospectively collected data from study sites.  Other analyses will use 
administrative claims data from patients on 
 health plans (i.e., 
 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
10
) and targeted non-
 plans.  
 
 
Patient characteristics, treatments and outcomes will be tabulated and summarized with 
descriptive statistics.  The descriptive statistics will include means, medians, standard deviation 
(SD), minimum, maximum and interquartile range (IQR) (difference between the 25th and 75th 
percentiles) for continuous variables and counts and relative frequencies for categorical data.  
The descriptive statistics will be presented for the study population overall and by treatment arm. 
Raw data (i.e., minimum and maximum values presented for range in continuous variables) will 
be reported out to the precision with which it was collected.  Means will be reported to 1 decimal 
place more than the raw data.  The standard deviation will be reported to 1 decimal place more 
than the mean.  Percentages will be reported to 1 decimal place.  Trailing zeros will be presented 
to maintain a consistent level of precision, e.g. 2.0 rather than 2. 
4.2 Sample Size Determination 
The sample size calculated for this study is 3200 patients with approximately 1600 patients in 
each treatment group.  Sample size calculations are summarized in the study protocol (Section 
6.3, Sample Size Determination). Due to early study termination, the actual sample size will be 
approximately 703 patients.  
4.3 Missing Data 
Except where otherwise noted, missing data will not be imputed and will be excluded from 
calculations. 
4.4 Data Definitions and Calculations 
4.4.1 Demographics 
Age will be presented in years based on the patient’s birth date and Baseline visit date.  The age 
(years) will be categorized as follows: 
• ≤55 years 
• >55 to ≤65 years 
• >65 to ≤75 years 
• >75 to ≤85 years 
• >85 years 
 
4.4.2 Treatment Variables 
COPD medication will be categorized as inhaled corticosteroid (ICS), long-acting beta agonist 
(LABA), long-acting muscarinic antagonist (LAMA), ICS-LABA, LAMA-LABA, ICS-LAMA-
LABA, short-acting beta agonist (SABA), short-acting muscarinic antagonist (SAMA), 
SAMA/SABA, phosphodiesterase 4 (PDE4) inhibitors, methylxanthines, therapies, or other 
based on the COPD Medication Categorization List in Appendix B.  This section will be updated 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
11
as necessary if new COPD therapies become available over the course of the study and are added 
to the eCRF. 
Pre-Study Treatment 
Pre-study treatment will be categorized into one of the qualifying maintenance therapies (LAMA 
monotherapy, LABA monotherapy, ICS/LABA fixed dose combination (FDC)) according to the 
COPD Medication Categorization List in Appendix B. 
On-Study Treatment 
Triple therapy is defined as any of the combination of ICS, LABA and LAMA drugs that a 
patient’s physician chooses.  Therefore, the following combination of COPD medications 
categories will count as triple therapy on study, differentiating between free combination and 
FDC: 
• Triple Therapy Free Combinations 
o ICS + LABA + LAMA 
o ICS-LABA + LAMA 
o ICS + LAMA-LABA 
• Triple Therapy FDC 
o LAMA-LABA-ICS 
Patients may switch or discontinue study treatment over the 12 month observation period. 
For the purpose of analysis, patients will be classified as Continued Original Randomized 
Treatment, Continued In-Class Randomized Treatment, or Off Randomized Treatment as 
described below.  The categories are non-overlapping.  Changes in targeted COPD concomitant 
medications do not apply to this classification. 
• Continued Original Randomized Treatment: Patients taking the same COPD 
medication as originally initiated for randomized COPD study treatment. 
o Stiolto Respimat patients taking Stiolto Respimat. 
o Triple Therapy patients taking the same individual components of ICS plus 
LAMA plus LABA as initiated at Baseline.  
• Continued In-Class Randomized Treatment: This definition only applies to Triple 
Therapy patients who made changes to the triple therapy components originally initiated 
for their randomized COPD study treatment (i.e., those not considered “Continued 
Original Randomized Treatment”).   
o Triple Therapy patients taking any combination of ICS plus LABA plus LAMA 
that meets the study definition of triple therapy will be considered “Continued In-
Class Randomized Treatment” if changed from original study medications. 
• 
  
 
  


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
12
• On Treatment: Patient is categorized as Continued Original Randomized Treatment or 
Continued In-Class Randomized Treatment (the duration of time is from randomization 
until the patient is no longer in one of these two categories) 
o Patients who have a temporary treatment interruption of ≤ 28 days will still be 
considered On Treatment provided they resume treatment that meets the On 
Treatment definition within 28 days of when the treatment was first interrupted. 
▪ If the On Treatment study medication is resumed with a new start date ≤ 
28 days of the stop date, it will be classified as a temporary treatment 
interruption. 
▪ If the On Treatment study medication is resumed with a new start of >28 
days of the stop date, or if the On Treatment study medication is not 
resumed before EOS or last contact, it will be classified as a treatment 
discontinuation. 
▪ For Triple Therapy patients, a >28 day continuous window in which they 
are not receiving all 3 components of triple therapy will be considered 
treatment discontinuation.  This could occur due to a >28 treatment 
interruption of a single component, or overlapping treatment interruptions 
of more than one component such that the patient does not receive triple 
therapy for a continuous window of >28 days. 
• Off Randomized Treatment: Patient is categorized as Off Treatment (the duration of 
time is from when the patient is no longer On Treatment until EOS or last contact) 
On Treatment will also be used for the safety analysis (Section 6.3). 
 
COPD Medication Class Categories 
The following targeted COPD concomitant medications will be defined for descriptive summary 
of COPD concomitant medication use by class at Baseline and EOS or last contact.  Baseline 
COPD concomitant medications will be medications with “On-Study Concomitant” status 
designated in the eCRF and a start date on or prior to the patient’s Baseline date.  EOS COPD 
concomitant medications will be medications designated “On-Study Concomitant” in the eCRF 
with a status of “Ongoing” at EOS or the latest medication entry. 
Targeted COPD Concomitant Medications at Baseline and EOS (Patients could contribute to 
multiple categories) 
• SABA only 
• SAMA only  
• SAMA + SABA (free or FDC) 
• PDE4 Inhibitors 
• Methylxanthines 
• Oxygen 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
13
• Not taking any targeted COPD concomitant medications 
The following Study COPD medication class categories will also be defined for descriptive 
summary of Study COPD medication at EOS or last contact: 
Study COPD Medications at EOS (Categories are non-overlapping) 
• LAMA only 
• LABA only 
• LAMA + LABA 
• ICS + LABA 
• ICS + LAMA + LABA 
• ICS-LAMA-LABA (FDC) 
• Not taking any Study COPD Medications 
• Discontinued all COPD Treatment: Patients not taking any COPD medication at EOS (no 
Study COPD medication use and no targeted COPD concomitant medication use). 
Additionally, the following definitions described below will descriptively report changes in 
Study COPD medication at EOS or last contact.  
• Original Randomized Treatment: Patients taking the same COPD medication at EOS 
as originally initiated for randomized COPD study treatment. 
o Stiolto Respimat patients taking Stiolto Respimat. 
o Triple Therapy patients taking the same individual components of ICS plus 
LAMA plus LABA as initiated at Baseline.  
• Step-Over In-Class Randomized Treatment:  This definition only applies to patients 
taking different treatment components at EOS as originally initiated for their randomized 
COPD study treatment (i.e., those not considered “Original Randomized Treatment”).   
o Triple Therapy patients taking any combination of ICS plus LABA plus LAMA 
that meets the study definition of triple therapy at EOS will be considered “Step-
Over In-Class Randomized Treatment” if changed from original study 
medications. 
o Stiolto Respimat patients taking a LAMA plus LABA regimen at EOS other than 
Stiolto Respimat. 
4.4.3 CAT 
4.4.3.1 
Overview 
The CAT will be administered at Baseline. It is a short (8-item), simple, patient-completed 
questionnaire that measures the impact of COPD on a patient’s well-being and daily life.1  
Patients rate the following items on a 6-point (0-5) scale, where higher scores indicate worse 
 
1 Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir 
J. 2009;34:648-654. 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
14
symptoms: Cough, Phlegm, Chest Tightness, Breathlessness, Activities at Home, Confidence 
Leaving Home, Sleep and Energy. 
The CAT instrument is attached in Appendix C. 
4.4.3.2 
Scoring and Categorization 
The CAT score will be calculated by summing responses from individual items, yielding scores 
ranging from 0-40, with higher scores indicating worse COPD-related health status.  Total CAT 
scores will be descriptively summarized. 
Total CAT scores will also be categorized as follows to enable Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) A-D classification: 
 
CAT < 10 
 
CAT ≥ 10 
For further descriptive summary, total CAT score will also be categorized as follows: 
CAT < 10 
 
CAT 10 to 20 
  
CAT 21 to 30 
CAT 31 to 40 
4.4.3.3 
Missing Data 
The CAT score is calculated as the sum of the responses present. If more than two responses are 
missing, a score cannot be calculated; when one or two items are missing, their scores will be set 
to the average of the non-missing item scores.1 
4.4.4 COPD and Exacerbation History 
Years with COPD will be calculated using Baseline visit date and COPD diagnosis date. 
COPD exacerbation history will be collected at Baseline as the number of moderate COPD 
exacerbations in the past year and the number of severe COPD exacerbations requiring 
hospitalization in the past year.  To enable GOLD A-D classification, the number of prior 
moderate and severe COPD exacerbations in the past year will be categorized as follows: 
• Moderate Exacerbations (did not lead to hospitalization): 0, 1, ≥ 2 
• Severe Exacerbation (lead to hospitalization): 0, ≥ 1 
Additionally, to enable classification of a high risk subgroup, the following exacerbation history 
category will be defined: 
• ≥ 2 Moderate or Severe Exacerbations 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
15
4.4.5 GOLD A-D Classification 
Patient’s GOLD A-D classification will be defined at Baseline using CAT scores and 
exacerbation history as follows: 
• GOLD A 
o CAT <10 AND 
o Moderate Exacerbation = 0 or 1 AND Severe Exacerbation = 0 
• GOLD B 
o CAT ≥ 10 AND 
o Moderate Exacerbation = 0 or 1 AND Severe Exacerbation = 0 
• GOLD C 
o CAT <10 AND 
o Moderate Exacerbation ≥ 2 OR Severe Exacerbation ≥ 1 
• GOLD D 
o CAT ≥ 10 AND 
o Moderate Exacerbation ≥ 2 OR Severe Exacerbation ≥ 1 
If a patient is missing either exacerbation history or CAT score is missing, then GOLD A-D will 
not be defined for that patient. 
4.4.6 Baseline ICS Prior Use 
Patients will be categorized by prior ICS use (yes/no) at Baseline. Baseline prior ICS use is 
defined as reporting any ICS use with a start date prior to baseline. 
4.4.7 Blood Eosinophils 
Baseline blood eosinophil level will be reported as an absolute count and also categorized as 
follows: 
• <100 cells/uL 
• 100 to <300 cells/uL 
• 300 to <400 cells/uL 
• ≥400 cells/uL 
4.4.8 High Risk Classification 
A subgroup of high risk patients with baseline blood eosinophil count ≥300 cells/uL and at least 
two moderate or severe exacerbations in the 12 months prior to baseline will be identified. 
4.5 Analysis Assessments  
4.5.1 Primary Endpoint Assessment 
The primary endpoint is time to first moderate or severe COPD exacerbation over the 12 month 
study period.  This endpoint is based on eCRF data as defined below. 
An exacerbation must have at least two of the following symptoms reported on the eCRF as 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
16
occurring for ≥ 3 days: 
• Cough 
• Sputum production (volume) 
• Change in sputum color 
• Wheezing 
• Shortness of breath 
• Chest tightness 
Additionally, the exacerbation must have required at least one of the following treatments as 
reported on the eCRF: 
• Exacerbation treated with antibiotics 
• Exacerbation treated with systemic steroids 
• Hospitalization associated with exacerbation 
COPD exacerbations will be classified based on treatment categories above as follows: 
Moderate: Exacerbation treated with antibiotics and/or systemic steroids, but did not have 
hospitalization associated with it. 
Severe: Hospitalization associated with exacerbation. 
Time to first moderate or severe COPD exacerbation will be based on the patient’s baseline visit 
and onset of exacerbation date up to and including the time of the planned EOS visit at 12 
months.  If there is a discrepancy between patient report and hospital records for onset of a 
severe exacerbation, hospital records will be used.  
In the event of multiple COPD exacerbations, those occurring within 7 days duration of each 
other will be collapsed into one exacerbation event for analysis.  If the start date of a subsequent 
exacerbation occurs within 7 days of the determined end date of a previous exacerbation, these 
two exacerbations will be collapsed into one event for analysis.  In this case, the onset date will 
be the start date of the first event and the severity classification will be based on the treatment 
associated with the most severe exacerbation within the collapsed event. 
4.5.2 Secondary Endpoint Assessments 
Secondary endpoints include: 
• Annual rate of moderate or severe COPD exacerbations over the 12 month 
observation period 
• Time to first severe COPD exacerbation over the 12 month observation period 
• Annual rate of severe COPD exacerbations over the 12 month observation period 
• Proportion of patients with moderate or severe COPD exacerbations over the 12 
month observation period 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
17
The secondary analyses for these secondary endpoints will use the COPD exacerbation defined 
as moderate or severe (as applicable) as collected in the eCRF and defined in section 4.5.1 
above.  All moderate and severe exacerbations with onset until time of planned EOS visit at 12 
months will be included in these analyses. 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
18


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
19


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
20


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
21
5.0 STATISTICAL ANALYSES 
The following populations are defined for analysis and reporting. Before the database lock, the 
team will review only table shells, not populated with actual data, to avoid bias. 
5.1 Analysis Populations 
5.1.1 Intent to Treat (ITT) Population 
The ITT population includes all randomized patients allocated to their original randomized 
treatment group.  
5.1.2 Per Protocol (PP) Population 
No per-protocol set is defined and no analysis is planned.  
 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
22
5.1.4 Safety Population 
The Safety population includes all randomized patients who received a prescription of any study 
treatment (Stiolto Respimat or triple therapy).  
5.2 Patient Disposition and Accountability 
Patient disposition will be summarized for all enrolled patients.  This will include the number 
and percentage of patients in the ITT 
 
  The number and percentage 
of patients who complete the full study observation period, defined as those who complete the 
end of study visit, will also be presented. Additionally, the primary reason for not completing the 
study observation period will be tabulated for patients who terminated participation in the study 
early. 
5.3 Demographics and Baseline Clinical Characteristics 
Demographic and baseline clinical characteristics will be summarized for the ITT population 
overall and by treatment group.  Frequencies and percentages will be calculated for gender, race, 
ethnicity, smoking status, COPD exacerbation history categories, CAT categories, and GOLD A-
D Classification, as defined in section 4.4. The number and percentage of patients with at least 
one of the pre-specified comorbid conditions will also be summarized along with the relative 
frequencies of type of comorbid condition (congested heart failure, hypertension, coronary artery 
disease, peripheral vascular disease, cerebrovascular disease, type 1 diabetes mellitus (T1DM), 
type 2 diabetes mellitus (T2DM), depression/anxiety, osteoporosis, gastroesophageal reflux 
disease (GERD)).  Descriptive statistics will be calculated for continuous variables (age in years, 
years with COPD, baseline blood eosinophil count and baseline CAT score), as described in 
section 4.1. 
5.4 Treatment Regimen 
Pre-study COPD treatment regimen, prior Baseline ICS use, and reason for therapy escalation 
will be summarized for the ITT population overall and by treatment group.  Frequencies and 
percentages will be calculated for COPD drug class as defined in section 4.4.2 above. 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
23
Use of targeted COPD concomitant medications will be summarized at baseline. Frequencies and 
percentages will be calculated for Targeted COPD Concomitant Medications by COPD drug 
class as defined in section 4.4.2 above.  Additionally, use of free versus FDC of triple therapy at 
baseline will be summarized for Triple Therapy patients. 
EOS COPD treatment regimen will be summarized for the ITT population by treatment group, 
including frequencies and percentages by COPD drug class for Study COPD Medications and 
Targeted COPD Concomitant Medications as defined in section 4.4.2 above.  Frequencies and 
percentages will also be calculated for Original Randomized Treatment and Step-Over In-Class 
Randomized Treatment at EOS. 
 
5.5 Effectiveness Analysis 
5.5.1 Primary ITT Analysis 
The primary effectiveness analysis will address the primary objective of this study: to compare 
the time to first moderate or severe COPD exacerbation between Stiolto Respimat and triple 
therapy.  As the sample size is reduced (approximately 703 patients), the study is underpowered, 
so no test for non-inferiority of Stiolto Respimat compared to triple therapy will be performed. 
For the primary endpoint, COPD exacerbation defined as moderate or severe as collected in the 
eCRF will be used (section 4.5.1). 
The primary analysis for the primary endpoint will be performed using the ITT population. 
Patients will be analyzed using the treatment arm to which they are randomized, even if they 
switched or discontinued study treatment.  Patients will be censored at the time of last contact, 
death or day of planned EOS visit at 12 months (whichever occurs earlier), if they did not 
experience a moderate or severe COPD exacerbation before. This will be referred as ITT 
analysis. 
For the primary endpoint, i.e. time to first moderate or severe COPD exacerbation, the Cox 
proportional hazards model with baseline ICS prior use as a covariate will be used to estimate the 
hazard ratio (HR) (Stiolto Respimat versus triple therapy),and the two-sided 95% Wald 
confidence interval (CI).   
In addition, Kaplan-Meier curves will be presented with reported statistics including median 
survival time, as well as 95% CI for each group. If the median survival time is not reached, the 
first quartile will be reported instead. 
 
 
 
 
 
  


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
24
 
5.5.3 Secondary Analyses 
The secondary objectives of the study will be addressed through the secondary analyses detailed 
in the following sections.  All secondary analyses will follow the ITT analysis as defined in 
Section 5.5.1 and will utilize the site-based exacerbation data from the eCRF. 
5.5.3.1 
Annual Rate of Moderate or Severe Exacerbations 
This analysis will address the secondary objective to compare the annual rate of moderate or 
severe COPD exacerbations for patients on Stiolto Respimat with patients on triple therapy.   
The annual rate of moderate or severe exacerbations analysis will utilize a negative binomial 
model with fixed effect of treatment (Stiolto Respimat versus triple therapy), logarithm of 
observational time as offset, and baseline prior ICS use as a covariate.  Observational time is 
defined as a patient’s date of planned EOS at 12 months or last contact or death date (whichever 
occurs earlier) – Baseline visit date + 1 day.3  The rate ratio (Stiolto Respimat versus triple 
therapy) will be presented with  95% CI.  Rates and 95% CI of each treatment group will also be 
presented.  
5.5.3.2 
Time to First Severe Exacerbation 
This analysis will address the secondary objective to compare the time to first severe COPD 
exacerbation for patients on Stiolto Respimat with patients on triple therapy.  For this analysis, 
only COPD exacerbation defined as severe as collected in the eCRF will be used. 
As in the primary analysis described in section 5.5.1 above, this will be an ITT analysis. The Cox 
proportional hazards model with baseline ICS prior use as a covariate will be used to estimate the 
HR (Stiolto Respimat versus triple therapy),  and the two-sided 95% Wald CI. 
 
 
3 Programming note: Observational time will be divided by 365.25 because this analysis is annual rate. 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
25
5.5.3.3 
Annual Rate of Severe Exacerbations 
This analysis will address the secondary objective to compare the annual rate of severe COPD 
exacerbations for patients on Stiolto Respimat with patients on triple therapy.  This analysis will 
be conducted on the ITT population including all severe exacerbations during the study 
observation period even if a patient switches or discontinues their assigned randomized study 
treatment. 
The annual rate of severe exacerbations analysis will utilize the same negative binomial model 
with fixed effect of treatment (Stiolto Respimat versus triple therapy), logarithm of observational 
time as offset, and baseline prior ICS use as a covariate.  Observational time is defined as a 
patient’s date of planned EOS at 12 months or last contact or death date (whichever occurs 
earlier) – Baseline visit date + 1 day.3  The rate ratio (Stiolto Respimat versus triple therapy) will 
be presented with 95% CI.  Rates and 95% CI of each treatment group will also be presented. 
5.5.3.4 
Proportion of Patients with Moderate or Severe 
Exacerbations 
This analysis will address the secondary objective to compare the proportion of patients with at 
least one moderate or severe COPD exacerbation from Baseline to the day of planned EOS visit 
at 12 months for patients on Stiolto Respimat with patients on triple therapy.  The proportion of 
patients with a moderate or severe COPD exacerbation during the study observation period will 
be descriptively summarized overall, by treatment group, and by baseline prior ICS use.  A 
Cochran-Mantel-Haenszel (CMH) model with baseline ICS prior use as stratum will be used to 
estimate the Risk Ratio (RR) (Stiolto Respimat versus triple therapy) and Risk Difference 
(Stiolto Respimat – triple therapy) of moderate or severe COPD exacerbations along with  95% 
CI.  Unadjusted proportions will also be presented. 
5.6 Patient Reported Outcome (PRO) Analysis 
The impact of COPD on patients’ health and quality of life will be assessed at baseline via the 
CAT.  PRO analysis will be descriptive in nature and will not involve any statistical testing.  
Rather, summary statistics will be used to describe patient perceived health status impairment 
associated with COPD at baseline as described in section 4.4.3 above. 
5.7 Concomitant Medications 
Pre-specified targeted COPD concomitant medications will be collected at Baseline as well as 
during on-study visits and EOS if applicable.  The number and percentage patients taking on-
study targeted COPD concomitant medications (designated “On-Study Concomitant” in the 
eCRF data) at any time during the 12 month observation period will be summarized by COPD 
Medication and Category (Appendix B) for the population overall and by treatment group. 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
26


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
27


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
28


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
29


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
30


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
31


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
32


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
33


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
34
 
6.0 SAFETY 
6.1 AEs 
AEs collected during this study are defined in Section 7.1 of the Study Protocol. 
6.2 SAEs 
SAEs collected during this study are defined in Section 7.2 of the Study Protocol. 
6.3 Reporting and Analysis Periods 
AEs and SAEs will be reported from the time a patient signs consent until the EOS visit at 12 
months or until the patient discontinues the trial.  However, only “on treatment” AEs and SAEs 
will be included in analysis.  “On treatment” medications for each treatment arm are defined in 
section 4.4.2.  For the safety analysis time period, all AEs will be considered “on treatment” (see 
section 4.4.2) if the AE start date is within 21 days after the On Treatment study medication end 
date or until EOS, whichever comes first. 
6.4 Analysis 
All AE analyses will be reported on the safety population.  
6.4.1 AE Analysis 
AE analyses will be descriptive in nature.  No hypothesis testing is planned prospectively.  All 
analyses of AEs will be based on the number of patients with AEs and NOT on the number of 
AEs. 
SAE data will be drawn from the Boehringer Ingelheim Safety Database, while other AEs 
collected as per protocol through the eCRF will be drawn from the study database. AE data for 
analysis will be merged from all sources for analysis. 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
35
AEs will be coded using the current version of the Medical Dictionary for Regulatory Activities 
(MedDRA) coding dictionary at the time of reporting.  Summary tables and listings will be 
produced to compare the incidence of AEs across treatment groups, by Preferred Term 
(PT)/System Organ Class (SOC). 
The frequency and percentage patients experiencing AEs and SAEs will be summarized by SOC 
and PT for the safety population overall and by treatment group as follows: 
• All collected AEs, regardless of seriousness, relatedness, or collection context  
• AEs leading to study treatment discontinuation, dose modification or trial withdrawal  
• AEs leading to study treatment discontinuation (subset of the above table) 
• AEs with a reasonable causal relationship to study treatment 
• All SAEs 
• Fatal AEs (subset of all SAEs) 
• Listing of all SAEs 
There will be no subgroup analyses for safety. 
 
7.0 IMPORTANT PROTOCOL VIOLATIONS (IPVs) 
IPVs will be reported in a listing.  Potential IPVs include: 
• Inclusion or Exclusion criteria not met. 
• Informed Consent not documented prior to study randomization. 
• Initial prescription provided for randomized study treatment was incorrect. (This does not 
include changes to study medication subsequent to initiation of study treatment.) 
 
8.0 APPENDIX A: Randomization Development and Validation 
At the time of this writing, the randomization process used by 
 has been tested, 
validated, and approved by the Boehringer Ingelheim Statistical team assigned to this project.  
To summarize, this project entailed an evaluation of the process
 would use to 
generate a sample of 4000 patients using block randomization.  That process included a random 
seed generation using the R package (R-project.org) of a number between one and one million.  
This seed was then used to first generate a sample of 40 patients for electronic data capture 
(EDC) validation and duplication by Boehringer Ingelheim.  Following this initial validation and 
duplication by Boehringer Ingelheim, the same approved process was used to generate a sample 
of 4000 for duplication by Boehringer Ingelheim using a different random seed.  At the time of 
this writing, both of these data sets have been validated. 
For the final step, the actual randomization list was generated and passed to electronic data EDC 
while keeping all members of the statistical team from Boehringer Ingelheim blinded.  Treatment 
and Control terms in the test data set were replaced with ‘Stiolto’ and ‘Triple Therapy’ and a 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
36
column was added to the randomization Excel sheet to sequentially list all patients by block from 
1 to 4,000.  At the time of this writing, all steps of this process have been accomplished. 
 
 
9.0 APPENDIX B: COPD Medication Categorization List  
Category 
COPD Medication 
 
 
ICS  
AEROBID  
 
AEROBID-M  
 
AEROSPAN  
 
ALVESCO  
 
ARNUITY ELLIPTA 
 
ASMANEX 14 METERED DOSES 
 
ASMANEX 60 METERED DOSES 
 
ASMANEX HFA 
 
ASMANEX TWISTHALER 120 ME 
 
ASMANEX TWISTHALER 14 MET 
 
ASMANEX TWISTHALER 30 MET 
 
ASMANEX TWISTHALER 60 MET 
 
ASMANEX TWISTHALER 7 METE 
 
BECLOVENT 
 
BECLOVENT ORAL/BECONASE 
 
BUDESONIDE 
 
FLOVENT 
 
FLOVENT DISKUS 
 
FLOVENT HFA 
 
FLOVENT ROTADISK 
 
FLUNISOLIDE 
 
FLUNISOLIDE ANHYDROUS 
 
PULMICORT 
 
PULMICORT FLEXHALER 
 
PULMICORT TURBUHALER 
 
QVAR 
 
VANCERIL 
 
VANCERIL DOUBLE STRENGTH 
 
 
LABA  
ARCAPTA NEOHALER 
 
BROVANA 
 
FORADIL AEROLIZER 
 
PERFOROMIST 
 
SEREVENT 
 
SEREVENT DISKUS 
 
STRIVERDI RESPIMAT 
 
 
LAMA  
INCRUSE ELLIPTA 
 
SEEBRI NEOHALER 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
37
 
SPIRIVA HANDIHALER 
 
SPIRIVA RESPIMAT 
 
TUDORZA PRESSAIR 
 
 
ICS-LABA  
ADVAIR DISKUS 
 
ADVAIR HFA 
 
BREO ELLIPTA 
 
DULERA 
 
SYMBICORT 
 
 
LAMA-LABA  
ANORO ELLIPTA 
 
BEVESPI AEROSPHERE 
 
STIOLTO RESPIMAT 
 
UTIBRON NEOHALER 
LAMA-LABA-
ICS 
TRELEGY 
 
 
SAMA 
ATROVENT  
 
IPRATROPIUM BROMIDE 
 
 
SAMA/SABA 
DUONEB  
 
IPRATROPIUM BROMIDE / ALBUTEROL SULFATE 
 
COMBIVENT RESPIMAT 
 
ALBUTEROL / IPRATROPIUM BROMIDE 
 
 
SABA 
ALBUTEROL 
 
ALBUTEROL INHALATION SOLUTION 
 
ACUNEB 
 
PROAIR 
 
PROVENTIL 
 
VENTOLIN 
 
XOPENEX  
 
LEVALBUTEROL 
 
 
PDE4 Inhibitor 
DALIRESP 
 
ROFLUMILAST 
 
 
Methylxanthines 
THEOPHYLLINE 
 
AMINOPHYLLINE 
 
ELIXOPHYLLIN 
 
QUIBRON T/SR 
 
T-PHYL 
 
THEO X 
 
THEO-24 
 
THEO-DUR 
 
THEOCHRON 
 
THEOLAIR SR 
 
UNI-DUR 
 
UNIPHYL  


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
38
 
 
Therapies 
OXYGEN 
 
 
Other 
OTHER 
 


Boehringer Ingelheim 
 
SAP for Protocol 1237-0064 
Version 3.0 March 2021 
         CONFIDENTIAL 
 
39
11.0 APPENDIX C: COPD Assessment TestTM (CAT)